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Tuberculosis (TB) is an ancient disease, that has plagued people around the world for 
thousands of years. Its causative agent Mycobacterium tuberculosis (Mtb) was discovered 
in 1882 by Robert Koch. TB spreads by coughing and subsequent inhalation of infected 
aerosols. As a consequence, many people (an estimated one third of the world population) 
are (latently) infected. Only 10% of these people will fall ill, of which 60% in the first two 
years after infection and 40% later in life (1). Although healthy people can develop active 
TB, the progression to active disease is often caused by weakening of the immune system 
by diseases such as HIV, diabetes mellitus and malignancies or by the use of immune sup-
pressive medication (1). The most common symptom of active TB is productive coughing, 
caused by lung inflammation. Nevertheless TB can affect the entire body (which is more 
common in immune deficient patients) with a wide variety in symptoms (2). Even though 
TB treatment is available, TB has been the top infectious disease killer in the world for the 
last years (3). In 2018 an estimated 10 million people fell ill with TB and an estimated 1.2 
million patients died due to this disease in the same year (3), underlining the importance 
of treatment improvement. 
In the next chapters we will address how TB can be diagnosed, treated and modelled.
diagnosis
Active TB can be diagnosed by (liquid) culturing through measuring the time-to-positiv-
ity, which is regarded as the gold standard. However, since it can take 2-6 weeks before 
the culture results are known (due to the long replication time of Mtb of 20 hours), it 
is necessary to also implement other diagnostics. By microscopic evaluation with aura-
mine staining a mycobacterial infection can be detected when the bacterial load is high 
enough. This should be followed up by a molecular analysis to exclude an infection with 
other mycobacteria, particularly non-tuberculous mycobacteria. Since 2010 the WHO 
endorsed the use of the GeneXpert MTB/RIF for the diagnostics of TB and the screening 
for rifampicin resistance (4). This PCR test can diagnose a TB infection and genotypical 
rifampicin resistance in 2 hours (5). This is a substantial advantage compared to pheno-
typical resistance assessment (the gold standard), which can only be performed on Mtb 
cultures, which can take up to 6 weeks to culture. 
Another useful new clinical application is whole genome sequencing, which can be 
used for diagnosis, assessment of drug resistance, surveillance and source investigation by 
complete DNA sequencing of the Mtb genome (6). 
For the diagnostics of latent TB no gold standard test is available. However, it can be 
indirectly shown by detecting (memory) T-cell reactivity in response to Mtb antigens. 
The oldest test for latent TB is the tuberculin skin test (TST). By the injection of a 
purified protein derivate of tuberculine under the skin, an immune reaction of latently 
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infected patients will cause induration of the skin. However, as there is cross reactivity 
with the BCG-vaccine and other mycobacteria, this test is not very specific (7). Therefore 
the interferon-gamma release assays (IGRAs) have been developed. These blood tests 
(QuantiFERON and T-SPOT.TB) measure the interferon-y (INF-y) release of T-cells in 
response to Mtb specific antigens (ESAT-6 and CFP-10) in case of previous Mtb exposure. 
A disadvantage of both the TST and IGRAs is their inability to distinguish between recent 
and old infections as recent infections provide a substantial higher risk of progression to 
active disease and justify latent TB treatment (8, 9). Therefore in the latest version of 
the QuantiFERON test not only the CD4+ T-cell INF-y release is measured, but also 
the INF-y release of CD8+ T-cells, as a higher CD8+ T-cell response has been related to 
recent Mtb exposure (10). Another disadvantage of both latent TB tests is their inability 
to differentiate between active and latent disease, making treatment decisions even more 
complex. Based on this element several studies used active TB patients and patients with a 
low TB risk as surrogates to calculate the sensitivity and specificity of these latent TB tests. 
Consequently, the overall estimated sensitivity of for example the QFT-plus of 95.3% is 
the sensitivity for the diagnosis of active TB instead of latent TB (11).
Treatment
The standard treatment of active TB consists of isoniazid, rifampicin, pyrazinamide and 
ethambutol (HRZE) and takes at least 6 months. The long treatment duration and high 
pill burden hamper treatment compliance with a risk of the emergence of drug resistance 
and worse treatment outcomes as a result (treatment success rate of 85% globally in 
2017) (3, 12). When Mtb is resistant to the first-line drugs isoniazid and rifampicin it 
is called multidrug resistant (MDR) TB. In 2018, there were about half a million new 
cases of rifampicin-resistant TB (of which 78% MDR-TB). Approximately 23,000 of 
these MDR-TB patients had additional resistance to fluoroquinolones and at least one of 
the three second line injectables, referred to as extensively drug resistant (XDR) TB and 
even cases of totally resistant tuberculosis (Mtb resistant to all available TB-drugs) have 
been described (13). When patients are diagnosed with drug resistant TB the treatment 
duration has to be increased to at least 9 months, but more often to more than 1.5 years. 
Also the amount of drugs that has to be taken increases and it can take up to 14,600 pills 
to treat one person with drug resistant TB. The treatment success rate of MDR-TB is poor 
with 54% and drops down to even 30% in case of XDR-TB (3). Based on these numbers 
it is clear that the therapy has to be improved to increase the treatment success and besides 
shortening the treatment duration and lowering the pill load is highly required. 
Several strategies can be followed to achieve this goal. First of all, given the increased 
prevalence of drug resistant TB and the existence of even totally resistant TB, there is an 
urgent need for new drugs. Nevertheless, in the last decades only two novel TB-drugs 
came on the market; bedaquiline in 2012 and delamanid in 2013. Secondly, new regimens 
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with promising combinations of TB-drugs should be developed. In TB patients Mtb can 
be present as fast, slow and non-multiplying Mtb, with the last subpopulation being espe-
cially difficult to treat due to changes in the cell wall composition and their low metabolism 
compromising the efficacy of TB drugs (14, 15). These non-multiplying mycobacteria are 
considered the main reason for the prolonged treatment duration and are held responsible 
for disease relapse due to their hidden persistence (16). Therefore new regimens should 
ideally be based on combinations of drugs with different working mechanisms, to be 
active against all metabolic states of Mtb. Another way of therapy improvement could be 
the optimization of TB-drugs dosages. Most TB-drugs have been used for decades in the 
same dosage, while choices for the specific dose were not always based on optimal dose 
finding, but instead were financially driven, or based on the fear of adverse events (17). A 
different approach to increase the activity of drugs is trying to increase the intrabacterial 
drug concentrations. There is accumulating evidence that efflux pumps by the extrusion 
of TB-drugs facilitate the emergence of drug resistance (18, 19). By blocking these efflux 
pumps by efflux pump inhibitors such as verapamil, the intrabacterial drug concentration 
might increase and subsequently reduce the emergence of resistance (20).
Pre-clinical modelling
Good pre-clinical models are essential to assess the activity and efficacy of these new drugs 
(combinations) and to optimize drug dosages. However, the translation of the results of 
these pre-clinical models to clinical outcomes in TB patients is difficult, which has been 
shown in for example the ReMOX trail (21). This trial aimed for a treatment reduction of 
drug-susceptible TB from 6 to 4 months by the replacement of isoniazid or ethambutol by 
moxifloxacin which was based on promising in vitro and in vivo results (22-25). However, 
in patients it appeared to be unsuccessful (21). In order to prevent such future mismatches 
several international consortia, as for example PreDiCT-TB and ERA4TB, have been 
working on the development of an optimal pre-clinical research path (26, 27). By using 
a combination of different models, many different characteristics of TB-drugs can be as-
sessed such as drug activity against different Mtb subpopulations, as well as intracellular 
drug activity, driving pharmacokinetics and pharmacodynamics (PK/PD) parameters and 
drug resistance mechanisms. Pre-clinical drug activity assessment against non-multiplying 
Mtb is important since this subpopulation is held responsible for the long treatment dura-
tion of TB in order to prevent relapse (15). However, drug activity on this subpopulation 
is difficult to assess. As this subpopulation is not replicating, it will not grow on solid 
culture plates, making this population difficult to identify (28, 29). Besides, creation of 
non-replicating Mtb is a lengthy process (at least 6 weeks) of Mtb growth inhibition by 
for example nutrient or oxygen depletion (30, 31). An alternative dormancy model is 
the 18b dormancy model (32). This model uses the 18b Mtb strain which is dependent 
on streptomycin for growth and without streptomycin it becomes non-multiplying. In 
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this non-multiplying state comparable “dormancy” genes are up regulated as in other 
dormancy models. Furthermore, the advantage of the 18b strain compared to these other 
dormancy models is that it becomes non-multiplying in only 10 days and has the ad-
ditional benefit that it can be cultured on culture plates containing streptomycin (33). In 
this way the activity of drugs against fast- and non-multiplying Mtb subpopulations can 
be determined simultaneously. Consequently, this strain can be easily used in for example 
time-kill-kinetics assays. These assays could be a useful tool to assess concentration and/or 
time dependent activity against different mycobacterial subpopulations (34). In time-kill 
kinetics assays, static concentrations are used, while in humans drugs concentrations vary 
depending on its absorption rate and half-life time. In a hollow fiber infection model, 
these pharmacokinetic parameters can be simulated. Besides, more frequent sampling for 
assessment of the bacterial load and drug concentrations is possible compared to other 
in vitro and even in vivo models (35). In this way the driving PK/PD parameters can 
be revealed (36), providing tools for optimal dose finding. In addition to these in vitro 
models, there is an important role for in vivo murine TB-models for the assessment of 
drug efficacy, allowing assessment of culture negativity as well as relapse (cure), which 
could be followed by mathematical modelling in order to improve the predictive value and 
thus the translation into clinical practice (37). 
ThesIs ouTlIne
The overall aim of this thesis is improving treatment of latent TB by better determination 
of the indication for treatment by a new diagnostic test (chapter 2), as well as improving 
the treatment of active TB (chapter 3 & 4). 
In chapter 2 the validation of the (at the time) new QuantiFERON-TB Gold Plus 
assay against its predecessor QuantiFERON-TB Gold In Tube is described. Besides, the 
additional value of CD8+ T-cell activity measurement to distinguish between recent and 
distant infection in the new QuantiFERON test was assessed in this study. This distinc-
tion is relevant as a recent TB infection provides a higher risk of progression to active 
disease and therefore could be used as a justification for treatment.
In chapter 3 the treatment shortening potential of different combination regimens for 
the treatment of active TB was explored. The new combination of the youngest TB-drugs 
bedaquiline, delamanid and linezolid was assessed in our mouse TB-model, by using a 
two-weekly relapse assessment and additional mathematical modelling (chapter 3.1). In 
the second murine TB study the additional value of the use of an efflux pump inhibitor 
was investigated, by adding verapamil to the combination of moxifloxacin and linezolid 
(chapter 3.2). 
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The chapter 4 focuses on the improvement of the predictably of two in vitro models for 
the treatment of active TB. The first study described improvement of the 18b dormancy 
model by the addition of time-to-positivity assessment and measurement of differences in 
area under the curve of time-kill-kinetics assays to allow better comparison of TB drug 
activity against multiplying and non-multiplying 18b (chapter 4.1). The second study as-
sessed whether the hollow fiber infection model is a useful tool to evaluate dosage increase 
of rifampicin and rifapentine (chapter 4.2).
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chapter 2
Improving diagnostics of latent TB infection 

chapter 2.1
A multicentre verification study of the 
Quantiferon®-TB Gold Plus assay 
E.D. Pieterman, F. Liqui Lung, A. Verbon, H.I. Bax, C.W. Ang, J. Berkhout, G. Blaauw, A. 
Brandenburg, N.D. van Burgel, A. Claessen, K. van Dijk, M. Heron, M. Hooghiemstra, R. 
Leussenkamp-Hummelink, E. van Lochem, I.H.M. van Loo, B. Mulder, A. Ott,  
O. Pontesilli, A. Reuwer, P. Rombouts, V. Saegeman, M. Scholing,  
S. Vainio, J.E.M. de Steenwinkel
Tuberculosis (Edinb). 2018 Jan;108:136-142
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ABsTrAcT
Objectives: The aim of this verification study was to compare the QuantiFERON®-TB 
Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new 
QFT-Plus test contains an extra antigen tube which, according to the manufacturer ad-
ditionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the 
value of this tube in detecting recent latent tuberculosis infections.
Methods: Between May 2015 and December 2016, 1031 subjects underwent the QFT-
Plus and QFT-GIT test. Overall agreement between both tests and performance for 
different test indications and/or immune states was assessed. A difference of >0.6 IU/mL 
interferon-g release between the two antigen tubes of the QFT-Plus assay was considered 
a true difference and used as estimation for CD8+ T-cell response. 
Results: Analysis of the QuantiFERON tests resulted in an overall agreement between 
assays of 95%. Subjects considered to be recently exposed to tuberculosis had signifi-
cantly more often a true difference in interferon-g release compared to all other subjects 
(p=0.029).
Conclusion: Results of QFT-Plus are highly comparable to QFT-GIT. Although there is 
an indication that a true difference in interferon-g release between the antigen tubes is 




Tuberculosis is still a major global health problem, with an estimated 10.4 million people 
suffering from this disease worldwide in 2015 (1). Moreover, about one third of the world 
population is latently infected with Mycobacterium tuberculosis (Mtb) and as such there 
is a vast reservoir (2). Once latently infected, the estimated lifetime risk to develop ac-
tive tuberculosis is 5-15% (3). Therefore, the goal of the World Health Organisation to 
effectively eliminate tuberculosis by 2050 is only feasible if we can identify and eliminate 
latent tuberculosis infections (LTBI) (4). 
LTBI are difficult to diagnose, because there is no gold standard test. The diagnosis is 
based on a positive tuberculosis skin test (TST) and/or interferon-g (IFN-g) release assay 
(IGRA) in the absence of active tuberculosis. The TST is based on an immune reaction in 
the skin towards purified protein derivate of tuberculine. The main limitation of this test is 
the cross reactivity with Bacillus Calmette-Guérin (BCG) vaccination and infection with 
other mycobacteria (5). In order to overcome this limitation, the IGRAs have been de-
veloped. Until recently two IGRAs were commercially available; the QuantiFERON®-TB 
Gold In-Tube (QFT-GIT) and the T-SPOT®.TB. By using Mtb derived specific peptides 
(ESAT-6, CFP-10 and TB7.7, the last one only in QFT-GIT) located in the region of dif-
ference (RD-1 and RD-11) of Mtb, IGRAs could elicit a more specific immune reaction 
compared to TST, characterized by IFN-g production in case of previous Mtb exposure 
(6). Nonetheless, also the IGRAs show cross reactivity with some other mycobacteria 
that contain the RD1 region (e.g. Mycobacterium marinum, Mycobacterium kansasii and 
Mycobacterium szulgai) (7). The disadvantages of IGRAs compared to the TST are their 
alleged reduced sensitivity for the detection of infections in the distant past as well as the 
higher costs (8, 9). The TST and IGRAs both rely on an appropriate immune reaction 
and have therefore theoretically a reduced sensitivity in immunocompromised patients 
(10, 11). Moreover, all these tests are unable to distinguish between recent and old latent 
infections (12). Such a differentiation is of importance, since the risk of developing active 
disease is highest in the first two years after infection, justifying LTBI treatment (13).
In 2015 a new QuantiFERON test has been introduced: the QuantiFERON®-TB 
Gold Plus (QFT-Plus) which will replace the currently used QuantiFERON-TB Gold 
in Tube (QFT-GIT). For this new test the peptide TB7.7 is removed and it contains an 
extra antigen tube (TB2) compared to its predecessor QFT-GIT. The additional tube 
contains adapted peptides, developed to target not only CD4+ T-cells, as the antigen tube 
of QFT-GIT and the TB1 antigen tube of QFT-Plus, but also CD8+ T-cells (14, 15). 
A previous study showed a higher CD8+ T-cell response in persons recently exposed to 
tuberculosis compared to exposure in the distant past (16). Therefore the QFT-Plus test 
might be capable of differentiating between recent and remote LTBI, which might help in 
the decision to start LTBI treatment.
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In this study we evaluated the performance of the QFT-Plus assay in the daily practice 
of 16 laboratories in the Netherlands and Belgium. Besides, we assessed the value of the 
additional tube of QFT-Plus in differentiating between recent and old LTBI. 
mATerIAls And meThods
study design and participants
We conducted a comparative verification study in 16 clinical laboratories in the Neth-
erlands and Belgium. From May 2015 till December 2016 subjects referred for Quan-
tiFERON testing to one of the participating laboratories were enrolled in this study. 
Participants underwent the regular QFT-GIT (Qiagen, Hilden, Germany) as well as the 
new QFT-Plus test (Qiagen, Hilden, Germany). Information on age, gender, immune 
state and test indication was collected by the local laboratory and forwarded anonymously 
for data analysis. 
QfT-GIT and QfT-Plus diagnostics
Whole-blood samples of all participants were (according to manufacturer’s protocol) 
either collected directly in QuantiFERON test tubes or pre-tubed in heparin tubes. The 
tests were performed and interpreted following regular laboratory procedures, according 
to the manufacturer’s guidelines (14). The test was recorded positive if the IFN-g release 
in the antigen tube (TB for QFT-GIT, TB1 and/or TB2 for QFT-Plus) minus the nega-
tive control (nil tube) was ≥0.35 IU/mL and ≥25% of the negative control. A test was 
considered negative if the IFN-g release of the antigen tube minus the negative control was 
<0.35 IU/mL or <25% of the negative control provided that the positive control (mitogen 
tube) was ≥0.5 IU/mL. A test was considered indeterminate if the IFN-g release of the 
negative control was >8 IU/mL or the antigen tube minus the negative control was <0.35 
IU/mL or <25% of the negative control with a positive control of <0.5 IU/mL (14).
statistical analysis
The agreement of both tests was assessed by calculating the percentage of concordant 
results and by computing the Cohen’s Kappa. We performed chi square tests to analyse 
whether there were any significant differences in agreement of both tests according to dif-
ferent immune states and test indications. Data are expressed as mean ± standard deviation 
(SD) or as median and interquartile range (IQR).
We performed the Wilcoxon signed rank test to evaluate whether there was a signifi-
cant difference in IFN-g release between both tests. Bland-Altman plots were created to 
identify any systematic differences in IFN-g release among both tests. Reference lines 
show mean and 95% limits of agreement (average difference ± 1.96 SD of the difference) 
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(17). Linear regression analyses were performed to assess the correlation of IFN-g release 
between both tests. The same analyses were performed to assess the differences between 
TB1 and TB2 results of the QFT-plus assay. For all analyses IFN-g release was calculated 
as the release of the antigen tube (TB, TB1 or TB2) minus the nil tube as the nil value for 
both tests could be different. 
To evaluate whether IFN-g release of CD8+ T-cells is related to recent exposure to 
tuberculosis, we subtracted the IFN-g release in antigen tube TB1 from antigen tube TB2. 
A difference in IFN-g release of >0.6 IU/mL was considered a true difference instead of 
intra-test variability based on the expected normal range of within-subject variability of 
IFN-g release on retesting (18). We calculated the percentage of subjects with an estimated 
true difference of IFN-g release within the positive test results, for each test indication. In 
addition, we performed chi square analyses to assess whether the differences between test 
indications were statistically significant. 
Statistical analyses were performed using IBM Statistical Package for Social Sciences 
(SPSS Inc., Chicago, IL, USA; version 22.0). The statistical significance level adopted was 
p <0.05.
medical ethical approval
All data were retrieved by the local diagnostic laboratory and forwarded anonymously for 
data analysis. No informed consent is needed for such data.
resulTs
The patient characteristics are shown in table 1. A total of 16 laboratories participated in 
this study and the samples of 1031 subjects were analysed. The majority of the subjects 
was immunocompetent (56%), 17% was immunocompromised and for 27% of the cases 
the immune state was unknown. The most frequent test indication was screening before 
immunotherapy (33%), followed by tuberculosis infection in differential diagnosis (25%), 
periodic check (every half year) by occupational health services of health care workers 
working with tuberculosis patients or possibly Mycobacterium tuberculosis infected materi-
als (18%) and contact investigation (12%). 
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QfT-GIT versus QfT-Plus
In 981 of the 1031 tests performed, QFT-GIT results were similar to QFT-Plus which 
resulted in an agreement of 95% and a Cohen’s kappa of 0.828 (table 2a). The results of 
QFT-Plus, divided by TB1 and TB2, compared to QFT-GIT showed an agreement of 
95% and a Cohen’s kappa of 0.806 and 0.835, respectively. No significant differences 
in agreement of QFT-GIT and QFT-Plus for different immune states or test indications 
were observed (p=0.554 and p=0.308, respectively). In table 2b, the discordant results 
are specified according to immune state and test indication. Since these were all small 
numbers, no statistical analysis has been performed. The discordancy was two-sided and 
60% was in the borderline range of 0.25-0.8 IU/ml (18). 



















Tuberculosis infection in differential diagnosis 
Contact investigation
Screening before immunotherapy 











2  Screening of immigrants 31 (3%), screening of homeless 5 (0.5%), employment medical examination 10 (1%), other 11 (1.1%)








QfT-GIT positive 131 222 0 153
QfT-GIT negative 191 835 54 859
QfT-GIT indeterminate 0 43 15 19
Total 150 861 20 981/ 1031
QFT-GIT: QuantiFERON®-TB Gold In-Tube, QFT-Plus: QuantiFERON®-TB Gold Plus. Bold numbers are concordant results. Discor-
dant results are highlighted in different colours and the numbers in superscript refer to table 2b. 

































































































































































































































































































































































The median IFN-g release of QFT-GIT positive results in TB 2.460 IU/mL (IQR: 0.810 
- 7.398) was significantly higher (p<0.001) compared to the median IFN-g release of 
QFT-Plus TB1 2.010 IU/mL (IQR: 0.385 - 6.195) and significantly lower (p<0.001) 
compared to the median IFN-g release of QFT-Plus TB2 2.470 IU/mL (IQR: 0.570 - 
6.070). However, there was no significant difference (p=0.673) in the median IFN-g 
release of QFT-GIT negative results of TB 0.000 IU/mL (IQR: -0.010 - 0.020) compared 
to the median IFN-g release of QFT-Plus TB1 0.000 IU/mL (-0.010 - 0.020). The me-
dian IFN-g release of TB2 0.005 IU/mL (IQR: -0.010 – 0.030) was significantly higher 
(p=0.003) compared to the median IFN-g release of TB of QFT-GIT negative results. 
The Bland Altman plots showed a minor positive systematic difference in IFN-g release of 
the QFT-GIT compared to the QFT-Plus (TB1 0.122 IU/mL, 95% limits of agreement: 
-1.528 - 1.772; TB2 0.067 IU/mL, 95% limits of agreement: -1.582 - 1.714) (figure 1A 
and 1C). Linear regression analyses showed a good correlation between both tests (TB1 
R2=0.896, TB2 R2=0.869) (figure 1B and 1D).
TB1 versus TB2 in the QfT-Plus assay
In 1002 out of 1031 tests, outcomes were similar in TB1 and TB2, resulting in an agree-
ment of 97% and a Cohen’s kappa of 0.893 (table 3a). In table 3b, the immune state and 
test indication of the subjects with discordant results are specified. 33% of the subjects 
who had a negative result in TB1 and a positive result in TB2, was tested in the context 
of contact investigation, compared to only 12% in the overall population. In the same 
group only 10% was tested in the context of screening before immunotherapy, while in 
the total population this was 33%. Since these are small numbers no statistical analysis has 
been performed. However, we did not find a significant difference in agreement of TB1 
and TB2 according to different immune states or test indications (p=0.531 and p=0.327, 
respectively). None of the TB1 positive / TB2 negative results had a difference in IFN-g 
release of >0.6 IU/mL, however 8 out of 18 TB1 negative / TB2 positive results had a 
difference in IFN-g release of >0.6 IU/ml.
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figure 1. Bland Altman plot (A, C, E) reference lines showing mean difference and 95% limits of agreement and 
regression plot (B, D, F) of IFN-γ release in TB antigen-nil vs TB1-nil (A, B), TB antigen-nil vs TB2-nil (C, D) 
and TB1-nil vs TB2-nil (E, F)
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Screening before immunotherapy (33%)





















In 33% of the positive tests performed in the context of either contact screening or peri-
odic check by occupational health services, the IFN-g release was >0.6 IU/mL higher in 
TB2 compared to TB1 (table 4). In the tuberculosis infection in differential diagnosis and 
screening before immunotherapy group this was only 17% and 11 %, respectively. These 
results were not significantly different (p=0.224). However, we observed a statistically 
Table 3a. Results QFT-Plus TB1 and TB2
TB2 positive TB2 negative TB2 indeterminate Total
TB1 positive 121 102 13 132
TB1 negative 181 861 0 879
TB1 indeterminate 0 0 20 20
Total 139 871 21 1002/
1031
QFT-GIT: QuantiFERON®-TB Gold In-Tube, QFT-Plus: QuantiFERON®-TB Gold Plus. Bold numbers are concordant results. Discor-
dant results are highlighted in different colours and the numbers in superscript refer to table 3b. 
Table 4. Difference in IFN-g between TB1 and TB2 >0.6 IU/mL in positive results
Test indication Ifn-g >0.6 Iu/ml
(% within positive results)
Tuberculosis infection in differential diagnosis 7 (17%)
Contact investigation 18 (33%)
Screening before immunotherapy 2 (11%)




*Screening of immigrants, screening of homeless, employment medical examination, other
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significant higher number of true differences in IFN-g release when the assumed recently 
exposed LTBI subjects (contact investigation group and periodic check by occupational 
health services group) are clustered and compared to the total of other test indication 
subgroups (p=0.029).
The IFN-g release of TB2 was higher (p<0.001) compared to TB1 in the QFT-Plus 
negative results with a median of 0.050 IU/mL (IQR: -0.010 - 0.030) versus 0.000 IU/
mL (IQR: -0.010 - 0.020). Within the positive results, a higher IFN-g release of TB2 was 
observed as well (p=0.001), with a median of 3.04 IU/mL (IQR: 0.848 – 6.288) versus 
2.345 IU/mL (IQR: 0.577 - 6.423). The IFN-g release in the indeterminate tests was 
not significantly different (p=0.218). Similarly, the Bland Altman plot showed a positive 
systematic difference of the IFN-g release of TB2 compared to TB1 (0.066 IU/mL, 95% 
limits of agreement: -1.263 - 1.395) (figure 1E). The linear regression analysis showed a 
good correlation (R2= 0.900) (figure 1F). The discordant results showed median values 
of IFN-g release around the cut-off of positive results, namely TB1 positive / TB2 nega-
tive; TB1 0.395 IU/mL (IQR: 0.377-0.607), TB2 0.178 IU/mL (IQR: 0.0085-0.283), 
TB2 positive / TB1 negative; TB1 0.248 IU/mL (IQR: 0.015-0.300), TB2 0.565 IU/mL 
(IQR: 0.398-3.218).
dIscussIon
To our knowledge this is the largest verification study of QFT-Plus performed so far, 
including different subject groups. In the present study executed in the Netherlands and 
Belgium, two low burden countries (19), QFT-Plus results were highly comparable with 
QFT-GIT. No significant differences between both QFT-tests were observed for different 
immune states and test indications. The discordant results were two-sided and the major-
ity was in the borderline range, suggesting that these discordant results might be due to 
test variability instead of true differences between tests (18). 
The most striking observation of this study was that one third of all positive tested 
contact screening subjects had a true difference in IFN-g release between TB1 and TB2 as 
well as one third of the positive tested subjects screened in the context of a periodic check 
by occupational health services. This was considerably more than for other subgroups. 
As we considered subjects in both screening categories are more likely to represent recent 
LTBI patients, these results might indicate that a higher IFN-g release in TB2 compared 
to TB1 is associated with recent tuberculosis contact. An Italian study among contact 
investigation subjects showed similar results and found a true difference in IFN-g release 
in 26% of all QFT-Plus positive tested contact screening subjects (20). Besides, in the 
same study a true difference between TB1 and TB2 was associated with a higher proximity 
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to the index case. Both findings are (indirect) indications that the TB2 is indeed associated 
with recent LTBI.
However, these results are in contrast with a study of Petruccioli et al. in which no 
higher IFN-g release in TB2 for TB contacts was observed (15). Furthermore, even a 
lower IFN-g release in TB2 compared to TB1 was measured in recent LTBI subjects. These 
differences in results might be due to the low number (N=12) of recent LTBI subjects 
enrolled in their study. 
In this study we observed 10 discordant results which were TB1 positive and TB2 
negative. Based on the assumption that TB1 only elicits a CD4+ T-cell reaction and TB2 
a CD4+ and a CD8+ T-cell reaction, these observations seem to contradict this. However, 
none of these results had a difference in IFN-g release of >0.6 IU/mL and might therefor 
be due to test variability (15, 18). 
In the present study we observed a significant lower IFN-g release of positive QFT-
GIT tests in TB1 tubes compared to the antigen tube of QFT-GIT. A possible explanation 
for this higher IFN-g release in QFT-GIT compared to TB1, might be the removal of 
the peptide antigen TB 7.7 in the new QFT-Plus test, which was present in QFT-GIT. 
Similar to QFT-Plus, a previous generation of the QFT-GIT (QuantiFERON®-TB Gold 
test) containing only ESAT-6 and CFP-10 peptide antigens, released significant less IFN-
g compared to QFT-GIT (21). The IFN-g release in TB2 was higher compared to the 
antigen tube of QFT-GIT. This might be the result of the adapted peptides added to TB2 
to elicit a CD8+ T-cell reaction besides the CD4+ T-cell reaction. These observations were 
comparable to previous studies also observing a significantly lower IFN-g release in QFT-
Plus compared to QFT-GIT and a lower IFN-g release in TB1 compared to TB2 (22, 23).
In this study we did not include active tuberculosis patients since IGRAs are not 
developed for the diagnosis of active tuberculosis. Therefore, associations between active 
TB and a higher IFN-g release in TB2 compared to TB1, as described in the majority of 
the previously published QFT-Plus studies, could not be studied. As mentioned, due to 
the absence of a gold standard sensitivity and specificity of QFT-Plus could not be assessed 
in a true matter. However, whether a real sensitivity and specificity could be obtained 
in the absence of a gold standard is debatable. Previous studies, performed with active 
tuberculosis patients as positive controls and low risk subjects used as negative controls, 
obtained a sensitivity of 89-90% and a specificity of 84-98% (22-25). This might indicate 
that the sensitivity and specificity remains approximately equal to QFT-GIT (90-94% and 
82-99% respectively) (22-24).
In conclusion, the present study showed an equal performance of QFT-Plus compared 
to QFT-GIT in a large multicentre study with various test indications and different im-
mune states. Although there is an indication that a higher IFN-g release in TB2 compared 
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ABsTrAcT
Background: The treatment success rate of drug-resistant tuberculosis (DR-TB) is alarm-
ingly low. Therefore, more effective and less complex regimens are urgently required. 
Methods: We compared the efficacy of an all oral DR-TB drug regimen consisting of 
bedaquiline (25 mg/kg), delamanid (2.5 mg/kg) and linezolid (100 mg/kg) (BDL) on 
the mycobacterial load in the lungs and spleen of TB infected mice during a treatment 
period of 24 weeks. This treatment was compared to the standard regimen of isoniazid, 
rifampicin, pyrazinamide and ethambutol (HRZE). Relapse was assessed 12 weeks post-
treatment. Two logistic regression models were developed to compare the efficacy of both 
regimens. 
Results: Culture negativity in the lungs was achieved at 8 and 20 weeks of treatment with 
BDL and HRZE, respectively. After 14 weeks of treatment only one mouse relapsed in the 
BDL group, while in the HRZE group relapse was still observed at 24 weeks of treatment. 
Predictions from the final mathematical models showed that a 95% cure rate was reached 
after 20.5 and 28.5 weeks of treatment with BDL and HRZE, respectively.
Conclusion: The BDL regimen was observed to be more effective than HRZE and could 
be a valuable option for the treatment of DR-TB.
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InTroducTIon
It is estimated that in 2018 10 million people developed tuberculosis (TB), of which 
500,000 contracted drug-resistant TB (DR-TB) (1). The treatment duration of DR-TB is 
at least 9 months, and frequently more than 1.5 years, requiring a combination of many 
different drugs. Even with this intensive therapy, the treatment success rate of DR-TB is 
only 54% in case of multi-drug resistant TB (MDR-TB) and 30% for extensively-drug 
resistant TB (XDR-TB) (1). Therefore shorter, less toxic and more effective regimens are 
required. 
Despite the urgent need for new treatments, only three new TB-drugs have become 
commercially available in the last four decades. Bedaquiline is the first member of a new 
class of drugs called diarylquinolines. Its mechanism of action relies on blocking a proton 
pump of Mycobacterium tuberculosis that is required for ATP synthase, resulting in the loss 
of energy production and cell death (2). Delamanid and pretomanid belong to another 
novel class of drugs, the nitroimidazoles. Exposure to delamanid blocks methoxy-mycolic 
and keto-mycolic acid synthesis causing destabilization of the mycobacterial cell wall 
(3). In addition to these new TB-drugs, linezolid has recently been repurposed as a core 
second line agent for MDR-TB and belongs to the oxazolidinones, which inhibit protein 
synthesis (4). 
Each of the drugs mentioned above possess different mechanisms of anti-mycobac-
terial action. Therefore, by combining the three orally administered drugs bedaquiline, 
delamanid and linezolid (BDL) we aimed to provide further evidence that this regimen 
can shorten DR-TB treatment duration. Experiments were performed in our previously 
validated mouse TB model using a drug-sensitive clinical M. tuberculosis strain (5, 6), and 
compared it with the standard regimen of isoniazid, rifampicin, pyrazinamide and etham-
butol (HRZE). We used a drug-sensitive strain as no ‘gold standard’ DR-TB regimen has 
yet been defined, enabling the comparison of the performance of the BDL regimen to that 
of the classical TB drug regimen HRZE as well as to other studies in this field (7). The 
treatment-shortening potential of the BDL regimen is supported by a hollow fibre model 
study, indicating the synergistic activity of the combination of bedaquiline and linezolid 
against M. tuberculosis in various metabolic states (8). A previous in vivo study investigated 
the combination of bedaquiline, pretomanid and linezolid (BPaL) in a mouse TB-model, 
showing good efficacy (9). Subsequently, this particular combination was assessed in the 
Nix-TB trial, with promising results regarding efficacy and safety in patients with either 
MDR- or XDR-TB (10). Studying the efficacy of delamanid in this DR-TB drug regimen 
(as a replacement for pretomanid) is of interest as some mutations in the deazaflavin-
dependent nitroreductase (ddn) enzyme are associated with resistance to pretomanid, but 
do not seem to affect susceptibility to delamanid (11). This is particularly relevant as such 
a mutation was already found to be present in a clinical M. tuberculosis Beijing strain 
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without the isolate ever being exposed to either pretomanid or delamanid (11). In this 
respect, delamanid could be a viable alternative for pretomanid in the BPaL regimen in 
cases of pretomanid resistance.
meThods
Animals
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les 
Oncins, France). Only female mice were used since some studies have shown different 
pharmacokinetic profiles between the sexes of mice (12). Animals were 13-15 weeks old 
at the start of the experiments, with experimental protocols adhering to the rules specified 
in the Dutch Animal Experimentation Act - concordant with the EU animal directive 
2010/63/EU (license numbers 117-14-04 and AVD1010020173687). 
Bacterial strain and TB-drugs
Experiments were performed using the drug-sensitive M. tuberculosis Beijing VN 
2002-1585 genotype strain (6) with MICs (mg/L) of isoniazid 0.125, rifampicin 0.25, 
ethambutol 5 (13), bedaquiline 0.06, delamanid 0.015 and linezolid 0.25. MICs were 
determined according to Clinical and Laboratory Standards Institute standards (14). The 
antibiotic drugs used were prepared as previously described (supplement 1) (5, 15). 
experimental set-up
Using previously described power calculations (supplement 2) (5), a total of 378 mice - 
210 for efficacy assessment and 168 for pharmacokinetic analysis - were needed. Mice were 
infected with M. tuberculosis suspensions as previously described (16). In short, a suspen-
sion of M. tuberculosis, stored at -80°C was defrosted at room temperature and centrifuged 
for 10 min at 14,000xg. The mycobacterial pellet was resuspended in phosphate-buffered 
saline (PBS) and centrifuged again for one minute at 1,900xg to eliminate any aggregated 
bacteria. The mycobacterial suspension was then diluted in PBS to obtain the intended 
bacterial load. Mice under anaesthesia were infected via intra-tracheal instillation with a 
suspension containing 1.2 (range 0.8-2.0) x 105 colony forming units (CFU) of M. tuber-
culosis, followed by inhalation to ensure the formation of a bilateral TB infection. Therapy 
was started two weeks after infection. Mice were checked daily, and were euthanized when 
humane endpoints (instability, dark eyes, decreased response to stimuli) were reached.
To assess the dose-response of monotherapy, mice were exposed to 0.5, 1 or 2 times 
the human pharmacokinetic equivalent doses (HED) of bedaquiline (i.e., 12.5, 25 or 50 
mg/kg), delamanid (1.25, 2.5 and 5 mg/kg) or 0.25, 0.5 or 1 time the HED of linezolid 
(25, 50 and 100 mg/kg). 
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Mice intended for combination therapy were divided into two groups. The first group 
received a combination of 25 mg/kg bedaquiline, 2.5 mg/kg delamanid and 100 mg/
kg linezolid (BDL). The second group received standard (HRZE) therapy i.e., 25 mg/kg 
isoniazid, 10 mg/kg rifampicin, 150 mg/kg pyrazinamide and 100 mg/kg ethambutol. 
All drugs were administered orally 5 times per week, using a feeding cannula and a total 
volume of 0.2 mL drug combination per day. 
Pharmacokinetic analyses
For quantification of the drug concentrations two blood samples per mouse were taken via 
venous tail puncture. Samples were taken after 4 weeks of treatment and for a period of 
24 hours. These 24 hour samples were taken in duplicate at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 
4, 6, 8, 12 and 24 hours post drug administration. Blood was collected in microcentrifuge 
tubes containing EDTA and centrifuged at 10,000xg for 5 minutes to obtain plasma, 
which was stored at -80°C. Methods for drug quantification by LC-MS/MS can be found 
in supplementary file 3.
PK/PD-parameters were determined using Prism 8 (GraphPad software, San Diego, 
CA, USA).
mycobacterial load (efficacy) assessment
Mice receiving bedaquiline monotherapy were euthanized 0, 1, 2 or 4 weeks after start 
of treatment (n=3 per dosage, per time point). Mice receiving delamanid or linezolid 
monotherapy were euthanized at 0, 1, 2 or 3 weeks after the start of treatment (n=3 per 
dosage, per time point) since they reached humane endpoints before week 4 due to severe 
TB infection. After euthanasia the mycobacterial load was measured by CFU counting for 
assessment of early bactericidal activity (EBA). For CFU counts, the lungs and spleen were 
removed aseptically and homogenized, followed by serial dilution and culture. In order 
to prevent drug carry-over, therapy was stopped 72 hours before euthanasia of the mice, 
with samples being cultured on 7H10 Middlebrook agar containing activated charcoal.
Mice receiving combination therapy (total 90 mice) were euthanized at the start of 
treatment (n=3) and - to assess the CFU count immediately after treatment - after a 
treatment duration of 8, 12, 16, 20 or 24 weeks (n=3 per time point). In order to assess 
relapse, mice were also euthanized 12 weeks after treatment was stopped, after a treatment 
duration of 8, 10, 12, 14, 16, 18, 20, 22 or 24 weeks (n=3 per time point) as described 
previously (supplement 4 ) (5). 
statistical analysis
CFU counts per mL were log10 transformed before analysis and multiplied by 2.3 and 2.1 
for lung and spleen, respectively. Group mean CFU counts were compared 3 or 4 weeks 
after the start of monotherapy (along with the control), using a one-way analysis of vari-
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ance with a Dunnett’s post-test to assess mono-activity. Differences in CFU count between 
the BDL and HRZE control groups were assessed at the start of treatment using unpaired 
two-sample t-test. The difference in cumulative time to relapse between both combina-
tion therapy groups was assessed using the log-rank test. The statistical significance level 
adopted was p <0.05. Analyses were performed using Prism 8 (GraphPad software).
A logistic regression model was used to predict the treatment lengths required to reach 
an 85%, 90% and 95% cure rate in mice treated with either the BDL or the HRZE regi-
men. CFU counts were transformed into a binary outcome variable, describing ‘relapse’ 
or ‘no relapse’. ‘Relapse’ was defined as a positive culture 12 weeks after discontinuation 
of treatment and ‘no relapse’ (i.e. cure) as a negative culture result. In order to describe the 
relationship between probability of relapse and treatment length, two logistic regression 
models, one for each regimen, were developed. During model development all parameters 
were estimated simultaneously using NONMEM software (version 7.4) (17). Model 
development is described in supplement 5.
In order to compare the efficacy of BDL and HRZE regimens, the cure rate at any 
treatment length, as well as the minimum treatment length needed to reach 85%, 90% 
and 95% cure, were predicted based on the final model for each regimen. Since the ob-
served data consisted of n=3 mice per time-point we could only create cure rates of 0%, 
33%, 67% and 100%, mathematical modelling was used to generate continuous cure rates 
between 0% and 100%. While in the logistic regression model the probability of relapse 
was modelled, the probability of no relapse, i.e. cure was used in the simulations. 
Since the probability of cure is the complementary probability to probability of re-
lapse, the probability of cure (Pcure) was obtained by subtracting the probability of relapse 
(Prelapse) from 1, as described in equation 1 in supplementary file 5. The proportion of 
cured mice was then simulated at each time-point. Predicted cure rates were simulated 
for treatment lengths between 0-30 weeks in 0.5 weeks increments for 1,000 mice per 
arm and time-point in order to achieve a high resolution in the predictions. Samples were 
randomly drawn from a uniform distribution using Monte Carlo sampling.
resulTs
Pharmacokinetics analyses
Plasma concentration-time profiles and pharmacokinetic parameters of the BDL combina-
tion and the metabolites of bedaquiline and delamanid are shown in figure 1 and table 1. 
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Table 1. Results of the pharmacokinetic analysis (n=2 per time point). Cmax is reported as the range of the maximum 
plasma concentration. The AUC(0-24h) is shown as mean with the standard error of the mean. 
drug (mg/kg) Tmax (hours) cmax (ng/ml) Auc(0-24h)(ng/ml*h)
Bedaquiline (25) 1.00 1,920-1,310 19,661 (1,121)
N-desmethyl-Bedaquiline 0.75 5,960-8,700 111,273 (6,312)
delamanid (2.5) 0.75 864-1,080 11,234 (841.7)
dm-6705 0.25 18.9-23.7 352.4 (34.9)
linezolid (100) 2.00 90,500* 251,269 (14,931)
*The drug concentration in only one mouse was assessed.
figure 1. Mice were treated with 25 mg/kg bedaquiline, 2.5 mg/kg delamanid and 100 mg/kg linezolid 5 times 
per week. Bedaquiline (A), N-desmethyl bedaquiline (B), delamanid (C), DM-6705 (D) and linezolid (E) plasma 
concentration-time profiles after 4 weeks of BDL therapy in TB-infected BALB/c mice. Plasma concentrations are 
plotted as mean ± SEM of two mice per study drug per time point.
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Pharmacodynamics analyses - mycobacterial load assessment 
During monotherapy, bedaquiline was well tolerated. However, mice treated with dela-
manid or linezolid showed stress during therapy and all mice receiving monotherapy of 
25 mg/kg linezolid were euthanized before 3 weeks of treatment as humane endpoints 
were reached. The mycobacterial load in the lungs during 3 or 4 weeks of treatment with 
bedaquiline (a), delamanid (b) and linezolid (c) are presented in figure 2. The median 
total amount of mycobacteria in the lungs at the start of treatment with bedaquiline was 
7.89 log10 CFU (range: 7.87-7.92), which declined significantly (p <0.01) after 4 weeks of 
treatment to 4.96, 4.55 and 5.28 log10 CFU, at 0.5x, 1x and 2x HED, respectively. Dela-
manid significantly reduced the CFU count in the lungs of mice after 3 weeks of treatment 
and at all doses tested (approximately 2 log10 CFU (p <0.001) were observed for all doses). 
Linezolid did not have a significant effect on the CFU count after 3 weeks of treatment (p 
=0.633). Results in the spleen were comparable for all drugs (data not shown).
figure 2. Mycobacterial load in lungs expressed as median ± range (error bars) of the colony forming units (CFU) 
(n=3), at week 0, 1, 2 and 3 or 4 weeks post treatment with bedaquiline (A), delamanid (B) or linezolid (C). The 
white bar represents the control mice, the bars from light to dark grey represent mice treated with 0.5, 1 and 2x 
HED, respectively. ** p < 0.01, *** p < 0.001 (one-way ANOVA). † 3 mice were euthanized before planned as 
humane endpoints had been reached. Results of one mouse treated with 0.5x HED, two mice treated with 1x HED 
and one mouse treated with 2x HED bedaquiline are missing in week 4, since no undiluted samples were analyzed 
and 10 times diluted samples of lungs and spleen did not show any CFUs.
Both BDL and HRZE combination treatments were well-tolerated. The mycobacterial 
load in lungs and spleen are presented in figure 3. The median total amount of mycobac-
teria in the lungs at start of BDL treatment was 7.80 log10 CFU (range: 7.66-8.07) and 
8.03 log10 CFU (range: 7.89-8.22) at start of HRZE treatment (p =0.256). At 8 weeks 
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of treatment with BDL culture negativity in the lungs and spleen was achieved. As of 16 
weeks of treatment, no relapse in the BDL group was observed, with the exception of one 
mouse in week 20. In HRZE treated mice, culture negativity in the lungs was achieved 
after 20 weeks of treatment. However, mice in this HRZE treatment arm relapsed (even) 
after 24 weeks of treatment. Results for the spleen showed a similar pattern. There were 
significantly fewer relapse episodes observed in the BDL group compared to the HRZE 
group (p <0.001) (Figure 4).
figure 3. Mycobacterial load in lungs (A, C) and spleen (B, D) expressed as median ± range (error bars) of the 
colony forming units (CFU) per organ. Results at weeks 8, 12, 16, 20 and 24 of treatment are expressed as white 
bars and relapse assessment was performed 12 weeks after a treatment duration of 8, 10, 12, 14, 16, 18, 20, 22 
and 24 weeks and expressed as grey bars. Mice were treated with BDL (A, B) or HRZE (C, D). Numbers above 
bars are the numbers of culture-positive mice out of total numbers of mice at that time point. * CFU counting was 
not performed since the culture plates were contaminated. † 1 mouse reached humane endpoints before planned 
euthanasia.
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figure 4. Cumulative relapse of mice treated with BDL or HRZE between 8 and 24 weeks. The solid line represents 
the BDL group and the dotted line the HRZE group.
Pharmacodynamics analyses - modeling
For the BDL regimen, none of the assessed functions that related treatment length and 
probability of relapse (linear, Emax and sigmoidal Emax function (supplementary file 6)) led 
to a significant improvement in model fit compared to the base model (p <0.05). Therefore, 
a ‘surge’ function was evaluated (in addition to the already assessed functions) as graphical 
analysis revealed an initial increase, followed by a decrease, in the probability of relapse 
as a function of treatment length (figure 3c). This use of a ‘surge’ function resulted in a 
statistically significant improvement in model fit compared to the base model (p <0.001) 
and was consequently retained in the final model relating length of BDL treatment with 
the probability of relapse. For the HRZE regimen, the probability of relapse in relation to 
different treatment lengths was best described by a sigmoidal Emax relationship. The model 
parameter estimates and parameter uncertainties are described in supplementary file 6.
The required treatment length of the BDL regimen to reach cure rates of 85%, 90% 
and 95%, was predicted to be 17.5, 18.5 and 20.5 weeks, respectively. For the HRZE 
regimen, simulations of the predicted cure rates at different treatment lengths showed that 
a 95% cure rate was reached after 28.5 weeks of treatment and for cure rates of 85% and 
90%, 26.0 and 27.0 weeks, respectively. A 95% cure rate was thus predicted to be reached 
8 weeks faster in mice treated with the BDL regimen compared to the HRZE regimen, 
which corresponds to a 28.1% decrease in treatment length. The predicted cure rates at 
different treatment lengths for both BDL and HRZE regimens are shown in table 2 and 
figure 5.
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Table 2. Comparison of model-predicted minimal treatment lengths required to reach 85%, 90% and 95% cure 
rates for both regimens. B = 25 mg/kg bedaquiline, D = 2.5 mg/kg delamanid and L = 100 mg/kg linezolid; H = 25 
mg/kg isoniazid; R = 10 mg/kg rifampicin; Z = 150 mg/kg pyrazinamide; E = 100 mg/kg ethambutol.
minimal treatment length required to achieve a cure rate of…(weeks)
regimen 85% 90% 95%
Bdl 17.5 18.5 20.5
hrZe 26.0 27.0 28.5
figure 5. Model predicted cure rates at different treatment lengths for both BDL and HRZE regimens. The dashed 
line represents 85%, the solid line 90% and the dotted line 95% cure rate. H = 25 mg/kg isoniazid; R = 10 mg/kg 
rifampicin; Z = 150 mg/kg pyrazinamide; E = 100 mg/kg ethambutol; B = 25 mg/kg bedaquiline, D = 2.5 mg/kg 
delamanid and L = 100 mg/kg linezolid.
dIscussIon 
The current study indicated a higher efficacy for the BDL combination treatment regimen, 
as compared to the standard HRZE regimen, when using a mouse TB-model and the 
clinically relevant M. tuberculosis Beijing genotype strain (6). In the early phase of treat-
ment, efficacy appeared to be mainly bedaquiline driven, as illustrated by the EBA results 
obtained using the three drugs separately as monotherapy. The observed dose dependent 
activity of bedaquiline was comparable to other murine studies (18, 19). Delamanid 
showed only minor bactericidal activity and linezolid no bactericidal activity in the first 
three weeks of monotherapy and mice were consequently euthanized one week before 
schedule. The limited EBA of delamanid is in line with other published murine studies. 
For example, one study showed a 2.5 log10 CFU/mL decrease after 28 days of treatment 
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with a dose of 2.5 mg/kg delamanid (3) and in another study a dose of 100 mg/kg (40 
times as much as in our study) reduced the CFU count in the lungs by 1 log10 after 4 weeks 
of treatment (20). In line with the present study, linezolid showed no bactericidal activity 
in previous murine studies (21). 
Our results indicated that a minimal treatment length of 20.5 weeks was predicted 
to be required in order to reach a 95% cure rate using the BDL regimen. This was 8 
weeks shorter than the HRZE regimen. Interestingly, two other murine studies assessed 
the efficacy of the combination of bedaquiline, pretomanid and linezolid (BPaL), showing 
good results for this combination regimen (9, 22). Xu et al. showed that the addition of 
pretomanid increased the bactericidal activity of the bedaquiline-linezolid combination 
and prevented the emergence of bedaquiline resistance (22). Although the individual con-
tribution of delamanid to the total efficacy of the BDL regimen was not assessed, it could 
be speculated that the same effect holds true for the contribution of delamanid in the 
current combination regimen. Further, the additional value of delamanid is supported by 
a study in MDR-TB patients showing increased sputum conversion when delamanid was 
added to a backbone treatment regimen (23). Moreover, the combination of bedaquiline 
and delamanid also appears to be promising in TB-patients. In studies reviewing the activ-
ity of these drugs in combination, 84% sputum conversion after 4 months of treatment 
(24) and 88% culture negativity after 24 weeks of treatment was observed when both 
drugs were added to a backbone regimen (92% of these patients also received linezolid) 
(25). Therefore, it is reasonable to assume that the BDL combination may also be a potent 
TB-drug regimen for patients, which would be in line with the first results of the Nix-TB 
trial studying the efficacy of BPaL in patients with MDR- and XDR-TB (10). 
As such, delamanid seems to be a reasonable alternative to pretomanid in specific 
situations such as pretomanid resistance(11, 26). Other murine studies showed robust 
efficacy of the combination of bedaquiline and pretomanid combined with moxifloxacin 
and pyrazinamide (BPaMZ) with a relapse free survival of only 2 months of treatment 
(22, 27). Given the results of our present study, it would be interesting to study whether 
the substitution of pretomanid for delamanid in the BPaMZ regimen results in similar 
efficacy.
In the present study, the EBA of linezolid as monotherapy was low, prompting 
questions about the contribution of this drug to the total efficacy of the BDL regimen. 
However, Tasneen et al. revealed the treatment shortening potential of linezolid in the 
BPaL regimen by showing that the addition of linezolid to the combination of bedaquiline 
and pretomanid resulted in no relapse in mice after 3 months of treatment, while mice 
treated with only bedaquiline and pretomanid relapsed after 4 months of treatment (9). 
These findings further strengthen the hypothesis that EBA should not be solely used as 
a guide for regimen efficacy (28). In addition, the efficacy of linezolid was assessed in 
patients with XDR-TB. The treatment success rate in the linezolid therapy group was 
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significantly higher (70%) compared to the non-linezolid group (34%) (29). Therefore, 
despite the disappointing performance of linezolid in terms of EBA, it appears to be a 
valuable component of the drug combination studied in this publication. 
Our pharmacokinetic results for bedaquiline, delamanid and linezolid fell within the 
range of those reported in previous murine TB studies(3, 30-32) and were also comparable 
to human pharmacokinetics (23, 33-35). Our bedaquiline concentration versus time 
curve showed a remarkable second peak after 8 hours of treatment. This second peak has 
not been observed in other murine studies (3, 30), although it has been reported in a 
human pharmacokinetics study (36). In this clinical study the double peak was explained 
by better absorption after food intake, which has also been shown in another study for 
rifapentine (37).
We also assessed the concentration versus time curves of the major metabolites of 
bedaquiline and delamanid, N-monodesmethyl bedaquiline (M2) and DM-6705 (M1), 
respectively. In humans, it is assumed that M2 does not have a significant effect on the 
total efficacy of bedaquiline since its exposure is 4-5 times lower, and the antimicrobial 
activity is 3-6 fold lower, compared to the parent compound (19). However, Rouan et al. 
showed that the exposure of M2 in mice (in terms of AUC) was three times higher com-
pared to bedaquiline (19) and in our study it was actually five times higher. Since the AUC 
is the driver of efficacy for bedaquiline, and M2 plus bedaquiline has an additive effect, 
the efficacy of bedaquiline in mice might be overestimated when translated to humans. 
However, this effect is assumed to be limited due to the lower antimicrobial activity of 
M2 (38). In our study the exposure of M1 was 32 times lower compared to delamanid, 
which is in line with the study of Sasahara et al. (32). Their study showed that, after 
repeated drug administration, metabolite exposure in humans was much higher compared 
to mice and rats. However, in our study, we reasoned that this finding did not lead to an 
underestimation of the effect of delamanid, since antimicrobial activity of the three major 
metabolites of delamanid (DM-6704, 6705 and 6706) was previously reported to be poor, 
with MICs ranging from 6.25 to 50 mg/L (39).
A limitation of this study was that it was powered on three mice every four weeks for 
CFU assessment immediately after treatment and three mice every two weeks to asses 
relapse, as based on previous modelling experience (5). Unexpectedly, we observed zero 
relapse after week 8, while in the following 6 weeks the proportion of relapsing mice 
increased. Subsequently after 14 weeks of treatment no mice relapsed, with the exception 
of one mouse in week 20. Although this could be a sampling artefact, this event resulted 
in an incomplete fit of the BDL regimen to the sigmoidal Emax model. This issue was 
overcome by using a Surge model, which enabled the assessment of expected treatment 
duration of the BDL regimen in relation to HRZE. Another limitation was the use of a 
drug sensitive strain for the assessment of this DR-TB regimen. However, many previous 
studies have also utilized drug sensitive TB strains to model DR-TB treatment regimens(9, 
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22, 27) and are now evaluated in clinical trials, and some of them already showing a good 
translation to clinical practice (10).
In conclusion, BDL seems to be a promising combination for the treatment of DR-
TB. Furthermore, since all three drugs are commercially available, this combination could 
be readily implemented in clinical practice after assessment in clinical studies and might 
be a good alternative for BPaL when pretomanid is not available for inclusion in combined 
TB treatment regimens.
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suPPlemenT 1.
Isoniazid (Erasmus MC Hospital Pharmacy, Rotterdam, The Netherlands), rifampicin 
(Rifadin®; Aventis Pharma B.V., Hoevelaken, The Netherlands), pyrazinamide and etham-
butol (both purchased from Sigma Chemical Co., St. Louis, MO, USA) were dissolved 
in distilled water. Bedaquiline was kindly provided by Janssen Pharmaceuticals (Johnson 
and Johnson, Machelen, Belgium) and dissolved in 20% cyclodextrine (Sigma Chemical 
Co) and distilled water and adjusted to a pH of 2.5. Delamanid was kindly provided 
by Otsuka Pharmaceutical Development & Commercialization (Rockville, USA) and 
linezolid was kindly provided by Janssen Pharmaceuticals. Both were dissolved in 20% 
cyclodextrine (Kleptose, Roquette NL BV, Hoofddorp, the Netherlands) and adjusted to 
a pH of 2.5. The combination of bedaquiline, delamanid and linezolid was dissolved in 
20% cylcodextrine and pH adjusted to 2.5.
suPPlemenT 2. 
This is a complete citation of the text in Mourik et al.(5).
“Statistical power analysis 
Aim
To determine the appropriate sample size in order to detect a statistically significant differ-
ence in potency between different treatment regimens. 
methods
The statistical power to detect a statistically significant difference, at the 5% significance 
level, in potency of 50% between different treatments were conducted at different sample 
sizes (n=2-5 animals per time point). Included time points were 2 to 6 months with 0.5 
month intervals (9 time-points in total). The power calculations assumed a sigmoidal Emax 
model with pbase of 1, Emax of 1, γ of 10 and a T50 of 2 months for treatment A (T50,A) 
and T50 of 4 months for treatment B (T50,B). One thousand simulations were performed 
at each sample size. The simulated data were re-estimated with one true model which 
included a difference in T50 between arms and an alternative model with no difference in 
T50. The proportion of re-estimated models where the true model (including difference 
between treatments) was significantly better than the alternative model (without difference 
between treatments) was the power at each sample size. In addition, the precision in the 
estimated parameters for the true model were also summarized. The estimated parameters 
were γ, T50,A and T50,B. Emax and pbase were both fixed to 1.
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results
The power to detect a significant difference in potency was: 87.9, 100, 100 and 100% 
for sample size of 2, 3, 4 and 5, mice per time point, respectively. This indicates that a 
sample size of 3 or more mice is sufficient to achieve 100% power to detect a statistically 
significant difference in potency between different treatments. The parameter precisions 
for n=3 expressed as relative standard error were 13.0, 0.8 and 0.2 % for γ, T50,A and 
T50,B, respectively which indicates that the expected parameter precision is reasonably 
high at n=3.
conclusion
A sample size of n=3 mice per time point is sufficient to detect a 50% difference in potency 
between different treatments and also gave reasonably high precision in model parameters 
(i.e. low parameter uncertainty).”
suPPlemenT 3.
LC-MS/MS analysis was performed on a Sciex Applied Biosystems Qtrap 6500+ triple-
quadrupole mass spectrometer coupled to an Shimadzu Nexera 2 HPLC system to quantify 
each drug in plasma. Delamanid and metabolites were quantified as published previously 
(40). Bedaquiline standard was received from Chemshuttle. N-monodesmethyl bedaqui-
line was purchased from Clearsynth. Linezolid was purchased from Sigma-Aldrich. Neat 
5 mg/mL DMSO stocks for bedaquiline, N-monodesmethyl bedaquiline, and linezolid 
were serial diluted in 50/50 acetonitrile/water to create standard curves and quality con-
trol (QC) spiking solutions. Standards and QCs were created by adding 10 µL of spiking 
solutions to 90 µL of drug free plasma (CD-1 K2EDTA Mouse, Bioreclamation IVT). 
20 µL of control, standard, QC, or study sample were added to 200 µL of acetonitrile/
methanol 50/50 protein precipitation solvent containing internal standards (10 ng/mL 
BDQ-d6 and 100 ng/mL LIN-d8). Extracts were vortexed for 5 minutes and centrifuged 
at 4000 rpm for 5 minutes. 100 µL of supernatant was transferred for HPLC-MS/MS 
analysis and diluted with 100 µL of Milli-Q deionized water.
Bedaquiline, N-monodesmethyl bedaquiline, and linezolid chromatography was 
performed on an Agilent Zorbax SB-C8 column (2.1x30 mm; particle size, 3.5µm) using 
a reverse phase gradient. Milli-Q deionized water with 0.1% formic acid was used for the 
aqueous mobile phase and 0.1% formic acid in acetonitrile for the organic mobile phase. 
Multiple-reaction monitoring of parent/daughter transitions in electrospray positive-
ionization mode was used to quantify the analytes. The following MRM transitions were 
used for bedaquiline (555.20/58.20), N-monodesmethyl bedaquiline (541.30/480.30), 
linezolid (338.00/235.00), BDQ-d6 (561.26/64.20), and LZD-d8 (346.15/304.20). 
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Sample analysis was accepted if the concentrations of the quality control samples were 
within 20% of the nominal concentration. Data processing was performed using Analyst 
software (version 1.6.2; Applied Biosystems Sciex).
suPPlemenT 4.
Study design combination therapy week 0-36, per regimen (BDL/HRZE).
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In a first step, the probability of relapse independent of treatment 
length was estimated for each regimen. This probability has been 
defined in equation 1 as base probability of relapse (Pbase) and can take 
any value between 0 and 1. In equation 1, Prelapse and Pcure are the 
probabilities of relapse and no relapse, i.e. cure.  
Pbase = Prelapse = 1-Pcure         (Eq. 1) 
To assess the effect of treatment length on the probability of relapse, 
the following modelling strategy was applied to both regimens 
separately. First, a function describing the probability of relapse 
linearly decreasing with treatment length was applied to the data for 
each regimen, as defined in equation 2, where Slope is the linear 
increase in probability of cure with treatment length and T is the 
treatment length in weeks. 
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suPPlemenT 5.
In a first step, the probability of relapse independent of treatment length was estimated 
for each regimen. This probability has been defined in equation 1 as base probability of 
relapse (Pbase) and can take any value between 0 and 1. In equation 1, Prelapse and Pcure are the 
probabilities of relapse and no relapse, i.e. cure. 
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 (Eq. 1)
To assess the effect of treatment length on the pr bability of relapse, the following model-
ling strategy was applied to both regim ns separa ely. First, a function describing the 
probability of relapse linearly d creasing with treatment length was applied to the data for 
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each regimen, as defined in equation 2, where Slope is the linear increase in probability of 
cure with treatment length and T is the treatment length in weeks.
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                                            Prelapse = 1-PCure = Pbase*(1-Slope*T)                  
(Eq. 2) 
Next, an Emax function, relating the probability of relapse in a non-
linear manner to treatment length, was tested (equation 3). 
                               Prelapse = 1-PCure = Pbase*(1-
Emax*T
T50+T
)        
(Eq. 3) 
In equation 3, T represents the treatment length in weeks, Emax the 
maximum reachable probability of cure, and T50 the time in weeks 
where the probability of cure is half-maximal.  
In addition, a sigmoidal Emax model was evaluated (equation 4).                                                    
                               Prelapse = 1-PCure = Pbase*(1-
Emax*Tγ
T50
γ +Tγ )                  (Eq.4) 
In the sigmoidal Emax relationship the Hill factor γ describes the 
steepness of the Emax relationship at the T50 value.  
Based on the results of the model evaluation and investigation of the 
raw data, we concluded that none of the above described relationships 
were appropriate to describe the probability of relapse dependent on 
treatment length for the BDL regimen. Therefore, a surge function 
describing the relationship between probability of relapse and 
treatment length was tested in addition for the BDL regimen (Equation 
5). 




             
               (Eq. 5)  
The surge function includes the surge amplitude (SA), which defines 
the maximum probability of relapse, the treatment lengths in weeks 
(T), the peak time (PT), which describes the time at which the 
maximum probability of relapse occurs in weeks, the surge width (SW), 
which defines half of the surge width in weeks, and a shape parameter 
(γ), that can take on even numbers. 
During model development the likelihood of a model to fit, i.e. 
describe, the observed data was evaluated and compared between 
 (Eq. 2)
Next, an Emax function, relating the probability of relapse in a non-linear manner to treat-
ment length, wa  test d (equation 3).
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The surge function includes the surge amplitude (SA), which defines the maximum prob-
ability of relaps , the tr atm n  lengths in weeks (T), the peak time (PT), which describes 
the time at which the maximum probability of relapse occurs in weeks, the surge width 
(SW), which defines half of the surge width in weeks, and a shape parameter (γ), that can 
take on even numbers.
During model devel pment the likelihood of a model to fit, i.e. describe, the observed 
data was evaluated and compar d between different applied models. The -2log likelihood 
for a model given the observed data, called objective function value (OFV), was compared 
to a reduced model using the likelihood ratio test (LRT). A statistically significant im-
provement, at the 5% significance level, of the model fit using a full model was indicated 
by a drop in OFV by at least 3.84 points for one degree of freedom, corresponding to the 
χ2 – distribution. In addition, all models were evaluated based on parameter uncertainties 
as well as visual predictive checks (VPCs). In a VPC, the observed data, here the propor-
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tion of mice that relapsed 12 weeks after stop of treatment, was graphically compared to 
data simulated from the model. 
The model building process and parameter estimation, as well as all simulations were 
conducted in NONMEM 7.43 (ICON plc, Gaithersburg, MD, USA)(17). Parameter 
estimation was performed using the conditional likelihood estimation method. Data 
management and visualization were carried out in R statistical software version 3.6.1 (R 
Foundation for Statistical Computing, Vienna, Austria)(41). Visual predictive checks 
(VPCs) were created using PsN 4.9.1 (Department of Pharmaceutical Biosciences, Up-
psala University, Uppsala, Sweden) and Xpose4(42).
Table e1. Final logistic regression model parameter estimates for the probability of relapse. H = 25 mg/kg isoniazid; 
R = 10 mg/kg rifampicin; Z = 150 mg/kg pyrazinamide; E = 100 mg/kg ethambutol; B = 25 mg/kg bedaquiline, D 
= 2.5 mg/kg delamanid and L = 100 mg/kg linezolid; CV = coefficient of variance
Regimen Parameter Description Parameter estimate
Standard error  
(% CV)
HRZE Pbase Baseline probability of relapse 1 FIX -
Emax Maximum reachable probability of cure 1 FIX -
T50 (weeks) Time at which Emax is half-maximal 22.6 6.4
γ Hill-factor 12.08 44.5
BDL N Shape parameter 2 FIX -
SA




Peak time, time at which maximum 
probability of relapse occurs
13.28 3.7
SW (weeks) Surge width, half of surge width 1.68 27.4
suPPlemenT 6.
The probability of relapse in relation to different treatment lengths for the HRZE regimen 
was best described by a sigmoidal Emax relationship. The model relating treatment length 
linearly to the base probability of relapse did not show a significant effect (p <0.05) of 
treatment with the HRZE regimen on relapse rate compared to the base model (drop in 
OFV = 3.16 for one degree of freedom), and was thus rejected. Also an Emax relationship 
did not describe the data significantly better (p <0.05) compared to the base model with a 
decrease in OFV of 2.80 for one degree of freedom. A sigmoidal Emax relationship however 
was able to describe the data statistically significantly (p <0.001) better than the base 
model. Compared to the base model without the effect of treatment length, the OFV 
dropped by 10.04 for two degrees of freedom when relating treatment length to prob-
ability of relapse in a sigmoidal Emax relationship. Therefore, the sigmoidal Emax model was 
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kept as the final model for the HRZE regimen. Due to the very steep relationship between 
treatment length and probability of relapse and the consequently high estimated Hill 
factor of 12.08, a drug effect could only be described with the sigmoidal Emax relationship. 
Since the base probability of relapse was estimated to 0.99 and therefore close to 1 it was 
fixed to 1, which allowed the parameter uncertainties to be obtained. The final model 
parameter estimates and parameter uncertainties are provided in supplementary table E1.
For the BDL regimen, none of the above described functions relating treatment 
length and probability of relapse led to a significant (p <0.05) improvement in model fit 
compared to the base model. Therefore, a surge function was evaluated in addition since 
the graphical analysis revealed an initial increase in probability of relapse followed by a 
decrease in probability of relapse as a function to treatment length (figure 3A). Due to 
numerical instability, the maximum probability of relapse (SA) was fixed to 1, since it 
was estimated very close to 1. The parameter N which describes the steepness of the surge 
function can take on even numbers. Different values for N (0, 2, 4, 6, 8, 10, 12, 14) were 
evaluated and the value leading to the lowest OFV was chosen. Compared to the base 
model, the OFV dropped by 10.00 points, which is statistically significant (p <0.001) for 
two degrees of freedom. The surge function was thus kept as final model relating length of 
treatment with the BDL regimen to probability of relapse.
VPCs of both final models are presented in Supplementary figure E1. As shown by the 
graphs, the observed proportion of relapse lies within the 95% confidence interval of the 
simulated data based on 1000 simulation datasets.
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suPPlemenTAry fIGures 
figure e1. Visual predictive checks (VPCs) of the final models. The open circles connected with the solid line rep-
resent the observed proportion of relapse and the shaded area is the 95% confidence interval of the model-predicted 
relapse rates at different treatment lengths. Panel a) represents the HRZE regimen: H = 25 mg/kg isoniazid; R = 10 
mg/kg rifampicin; Z = 150 mg/kg pyrazinamide; E = 100 mg/kg ethambutol. Panel b) represents the BDL regimen: 
B = 25 mg/kg bedaquiline, D = 2.5 mg/kg delamanid and L = 100 mg/kg linezolid.
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ABsTrAcT
Background: Favourable treatment outcome of multidrug resistant tuberculosis (TB) 
is only 54% and therefore new drug regimens are urgently needed. In this study, we 
evaluated the additional value of the efflux-pump inhibitor verapamil to a backbone of 
moxifloxacin and linezolid in a murine TB model.
Methods: BALB/c mice infected with Mycobacterium tuberculosis were treated with 
human-equivalent doses of moxifloxacin (200 mg/kg) and linezolid (100 mg/kg) with or 
without verapamil (12.5 mg/kg) for 12 weeks. Pharmacokinetic parameters were collected 
during treatment at steady state.
Results: After 12 weeks of treatment, the mycobacterial load in the lungs declined 5.0 
Log colony forming units (CFU) without verapamil and 5.9 Log CFU with verapamil 
(p<0.001) but sterilization was not achieved yet and the effect on relapse rates could 
therefore not be evaluated. The spleens of all mice were culture-negative after 12 weeks of 
treatment with both treatment modalities and addition of verapamil caused a significant 
reduction in relapse (14/14 positive spleens without versus 9/15 with verapamil, p=0.017).
Conclusion: The addition of verapamil did not significantly increase the effectiveness of 
a regimen consisting of moxifloxacin and linezolid in our mouse TB model, but data on 
relapse warrant follow-up studies with a longer treatment duration.
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InTroducTIon
Tuberculosis (TB) is the leading cause of death from infectious disease worldwide. An 
estimated 1.7 million people died due to this disease in 2016 and an estimated 10.4 
million people fell ill in the same year (1). Drug resistance remains a problem for the 
treatment of TB; an estimated 4% of the new TB cases and 19% of previously treated TB 
cases had rifampicin resistant or multidrug resistant (MDR) TB (1). Currently patients 
with MDR-TB need to undergo up to two years of treatment with toxic drugs, while only 
54 percent are cured (1). Novel treatment regimens that are both more effective, short and 
safe need to be developed to treat this devastating disease. 
In order to increase the treatment efficacy on the short term, we focused in this study 
on drugs which are already registered for use. Fluoroquinolones are considered to be 
among the most important groups of drugs in the treatment of MDR-TB, in particular 
moxifloxacin and levofloxacin (2, 3). In murine TB models moxifloxacin showed to be 
the most bactericidal of all quinolones. It also showed good activity against rifampicin-
tolerant TB and MDR-TB in different mouse TB models (4, 5). Furthermore, a random-
ized controlled trial showed promising success rates in patients with MDR-TB treated 
with a regimen including moxifloxacin (6). Therefore, moxifloxacin is now recommended 
by the World Health Organization (WHO) in their most recent guideline outlining a 
shorter MDR-TB regimen (8-12 months instead of at least 18 months treatment) for 
patients who were not previously treated with second-line drugs (7). 
In the current WHO treatment guideline, linezolid (an oxazolidinone) is classified 
as a core second-line agent (Group C) (7). In vitro and in vivo studies showed good ac-
tivity of linezolid against multiple MDR-TB strains (4, 8) and a systematic review and 
meta-analysis of patients treated with linezolid-containing MDR and extensively drug 
resistant (XDR)-TB regimens showed promising results (9). Furthermore, a meta-analysis 
of MDR-TB patients treated with (at that time) group 5 drugs showed that the use of 
linezolid increased the probability of a successful treatment outcome in this group by 57% 
(10). Ongoing studies include an evaluation of linezolid combined with bedaquiline and 
pretomanid in a short six month treatment for XDR-TB (Nix-TB) trial(11) and a phase 
3 study evaluating various doses and treatment durations of linezolid, bedaquiline and 
pretomanid in multi-drug resistant (MDR)- and XDR-TB patients (ZeNix trial) (12). 
Although the effectiveness of moxifloxacin and linezolid appears to be promising, the 
emergence of resistance to both drugs is a problem. There is accumulating evidence sup-
porting a role for mycobacterial efflux pumps in the extrusion of TB drugs and emergence 
of drug resistance to both fluoroquinolones as well as oxazolidinones (13, 14). Thus, inac-
tivation of these mycobacterial efflux pumps by efflux pump inhibitors (EPIs) could be a 
valuable strategy to increase intrabacterial drug concentrations and reduce the emergence 
of drug resistance (15).
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Verapamil was the first discovered inhibitor of P-glycoprotein mediated drug efflux 
(16) and showed to be able to increase the accumulation of P-glycoprotein substrate 
drugs in macrophages (17). Another study showed that macrophage-induced tolerance of 
moxifloxacin could be reversed upon exposure to verapamil (13). Furthermore, verapamil 
does not only affect macrophage efflux pumps, but has also been identified as an inhibitor 
of M. tuberculosis efflux systems (18-21).
In the present study, we evaluated the additional value of verapamil to a backbone 
of moxifloxacin and linezolid. We assessed the efficacy of this regimen in BALB/c mice 
infected with a M. tuberculosis strain of the Beijing genotype and evaluated the pharmaco-
kinetic profiles of drugs in this regimen.
resulTs
mycobacterial load (efficacy) assessment 
Both moxifloxacin + linezolid (group 1) and moxifloxacin + linezolid + verapamil (group 
2) combination treatments were well tolerated, although mice showed mild distress during 
the first three weeks of treatment in both groups.
In figure 1, the mycobacterial load in lungs and spleen during 12 weeks of treatment 
and after a 12 weeks post-treatment period is presented. The median total amount of my-
cobacteria in the lungs at start of treatment was 8.18 Log CFU (IQR: 7.96 - 8.19). During 
the 12 weeks of treatment the mycobacterial load in the lungs declined with 5.0 Log CFU 
in group 1 (p < 0.0001) and with 5.9 Log CFU in group 2 (p < 0.0001) compared to start 
treatment. No significant difference between group 1 and 2 was observed at this time 
point. No sterilization of the lungs was achieved with either of the treatment modalities. 
As a result, no assessment of relapse in lung tissue was possible. In contrast, the spleens 
of all mice were culture-negative after 12 weeks treatment. The addition of verapamil 
was associated with a significant reduction in relapse after three months of treatment, as 
measured in the spleen (9/15 culture positive samples in group 2 versus 14/14 in group 
1, p = 0.017).
Pharmacokinetic evaluation
Plasma concentration-time profiles and pharmacokinetic parameters of the study drugs 
are shown in figure 2 and table 1. 
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figure 1. Mycobacterial load in lung (a) and spleen (b) expressed as median ± range (error bars) of the colony form-
ing units per organ, at week 2, 6, 10 and 14 and at 12 weeks post treatment (week 26). Grey bars are mice treated 
with moxifloxacin and linezolid, striped bars are mice treated with moxifloxacin, linezolid and verapamil. Numbers 
above bars are the numbers of culture-positive mice out of total numbers of mice at that time point. Significance is 
noted as (**) p <0.0001 and (*) p < 0.05. † 1 mice became moribund before planned dissection.
CFU, colony forming units; LZD, linezolid; MXF, moxifloxacin; VPM, verapamil.
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figure 2. Moxifloxacin (a), linezolid (b) and (nor-)verapamil (c) plasma concentration-time profiles at steady state 
following an oral dose of 200 mg/kg moxifloxacin, 100 mg/kg linezolid and/or 12.5 mg/kg verapamil in TB-infect-
ed BALB/c mice. Plasma concentrations are plotted as mean ± SEM of three mice per study drug per time point.
CFU, colony forming units; LZD, linezolid; MXF, moxifloxacin; VPM, verapamil.
Table 1. Pharmacokinetic parameters at steady state of moxifloxacin and linezolid and (nor-) verapamil in plasma 













MXF (+ LZD) 200 30.0 6.6 0.15 0.92 4.3
MXF (+ LZD + VPM) 200 46.0 9.5 0.10 0.43 3.1
LZD (+ MXF) 100 215 32.7 0.010 0.028 1.9
LZD (+ MXF + VPM) 100 179 31.3 0.012 0.035 1.9
VPM (+ MXF + LZD) 12.5 2670a 365a 0.00010 0.00067 4.5
nor-VPM (+ MXF + LZD) NA 1387a 149a NA NA NA
Pharmacokinetic parameters are based on 8 time points; concentrations at each time point were based on plasma samples of 3 mice.
a For verapamil and nor-verapamil AUC0-τ and Cmax were expressed in µg/L*h and µg/L, respectively
AUC0-τ, area under the plasma concentration-time curve within the dosing interval; Cl, clearance; Cmax, maximum plasma concentration; 
F, bioavailability; LZD, linezolid; MXF, moxifloxacin; Vd, volume of distribution; VPM, verapamil.
The total exposure to moxifloxacin was 53% higher in the mice that received verapamil and 
also the peak concentration (Cmax) was 44% higher with addition of verapamil (9.5 versus 
6.6 mg/L). In contrast, the area under the plasma concentration-time curves (AUC0-24) of 
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linezolid was slightly (17%) lower in mice that received verapamil, whereas the linezolid 
peak concentrations in the two groups were approximately similar (31.3 and 32.7 mg/L). 
The total exposure of verapamil and its active metabolite nor-verapamil was 2670 µg/L*h 
and 1387 µg/L*h, respectively, with a Cmax of 365 µg/L and 149 µg/L, respectively.
dIscussIon
In the present study we evaluated whether verapamil could increase the treatment efficacy 
of a combination regimen consisting of moxifloxacin and linezolid in a murine TB model. 
The addition of verapamil did not significantly increase the treatment efficacy of this 
backbone. This is in line with the results of our in vitro study in which no additional 
effect of verapamil to moxifloxacin plus linezolid was observed (22). We hypothesized 
that applying this regimen to mice would result in a more prominent effect of verapamil 
compared to our in vitro study, since verapamil is supposed to affect not only the M. 
tuberculosis efflux pumps, but also the efflux pumps of macrophages. Such an effect on 
macrophages was shown by Adams et al. in an in vitro macrophage model where the 
addition of verapamil to moxifloxacin reduced tolerance against moxifloxacin (13). In 
addition, other studies showed promising effects of the use of verapamil in combination 
with several anti-TB drugs. For example Gupta et al. showed that verapamil could increase 
the treatment efficacy of a standard TB drug regimen consisting of rifampicin, isoniazid 
and pyrazinamide in mice (23). Similarly, it was shown for the new drug bedaquiline, that 
sub-inhibitory dosing of bedaquiline in a murine TB model could become as effective as 
regular dosing after the addition of verapamil (24). Both murine TB studies showed a 
significant difference of ± 1 Log CFU between regimens with and without verapamil on 
different time-points (23, 24). Gupta et al. also showed that the addition of verapamil 
could reduce the relapse rate of a standard TB regimen (23). In our study a significant 
reduction in relapse in the spleen was achieved in the mice that used verapamil. However, 
since all mice were culture positive it is difficult to assess the clinical value of this observa-
tion.
Although multiple randomized controlled trials showed promising treatment out-
comes of MDR-TB regimens containing linezolid or moxifloxacin, with success rates 
of approximately 80%, limited data are available on the combination of both drugs in 
humans (6, 25). Most studies on MDR-TB regimens containing linezolid in humans were 
either performed when moxifloxacin resistance was present or linezolid was added to a 
wide range of regimens (26, 27). However, previous in vitro studies provide some insight 
in the efficacy of combining both drugs. A pharmacokinetics-pharmacodynamics study of 
Deshpande et al. showed that the combination of moxifloxacin and linezolid could result 
in either a synergistic, indifferent or antagonistic effect based on their AUC0-24h/MIC 
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ratios (28). The AUC0-24h of moxifloxacin and linezolid in the present study were neither 
in the synergistic or antagonistic range.
Another study showed that the interaction between moxifloxacin and linezolid was 
strain dependent, although in most cases a synergistic effect was observed (29).
In our study the combination of moxifloxacin and linezolid achieved a load reduction 
of 5 Log CFU in the lungs after 3 months of treatment and the mycobacterial load in the 
spleens was undetectable at that time point. The treatment duration of 3 months appeared 
to be too ambitious to achieve sterilization in the lungs and therefore relapse could not 
be assessed. Given the strong reduction of bacterial load in the lungs by the linezolid and 
moxifloxacin backbone, it would be interesting to apply this regimen to an MDR-TB 
mouse model for an extended period of time. By extending the treatment duration, relapse 
reduction mediated by verapamil, as observed by Gupta et al., may possibly be replicated 
(23).
In order to evaluate the influence of verapamil on the pharmacokinetics of our back-
bone we compared the pharmacokinetic parameters of moxifloxacin and linezolid with 
and without verapamil. We observed that the total exposure to moxifloxacin was approxi-
mately 53% higher upon addition of verapamil. This effect could probably be ascribed to 
the inhibition of P-glycoprotein activity at the site of the intestines of the mice, as peak 
exposure was also amplified with 44% (30). However, this increased exposure did not 
result in a significant increased effect. In this context, it would be interesting to measure 
the drug concentrations in the macrophages to evaluate whether the use of verapamil also 
increased the drug concentrations intracellularly. Whether an increased intra-macrophage 
drug concentration will also lead to an increased effect is still unclear (15).
Next, we compared our observed AUC0-24 to clinically relevant AUC0-t exposures ob-
served in humans at steady state, to confirm exposure equivalence of the study drugs with 
human exposures. Total exposures to moxifloxacin (AUC0-t 30 mg/L*h) were comparable 
with the range of exposures found in humans (AUC0-24h 25-29 mg/L*h), which were 
obtained with the recommended 400 mg of moxifloxacin orally (31, 32). Similarly, total 
exposures to linezolid in our study were comparable to AUC0-12 values found in pharma-
cokinetic studies in humans after an oral intake of 600 mg linezolid twice daily (AUC0-12 
108-146 mg/l*h), assuming that AUC0-24 is twice the AUC0-12 (33, 34). Verapamil expo-
sure in our study mimicked the range as observed in humans, namely an AUC0-24h of 3253 
µg/L*h after daily oral intake of 240 mg of slow-release verapamil (35), and an AUC0-8h of 
1999 µg/L*h after thrice daily oral intake of 120 mg immediate-release verapamil with a 
nor-verapamil total exposure of 2312 µg/L*h (36). Based on these results we can conclude 
that drug exposures in the present murine study were comparable with those achieved in 
humans. Although total exposures were comparable to humans, the Cmax of moxifloxacin 
and linezolid in this study were higher compared to humans (6.6 mg/L vs 3.9 mg/L and 
32.7 mg/L vs 20.4 mg/L, respectively)(32, 33). Since the AUC/MIC ratio is considered 
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to be the driver of efficacy for moxifloxacin and linezolid (37, 38) and moxifloxacin Cmax/
MIC ratio showed a poor correlation in efficacy in BALB/c mice (38), we assumed that 
this has limited effect on the translational value.
A possible limitation for implementation of a linezolid containing regimen, is the 
known toxicity of linezolid. Therefore, it may be worthwhile to consider to replace line-
zolid with a new oxazolidinone, such as sutezolid. Sutezolid showed promising results in 
an in vitro study, with a bactericidal effect against non-replicating M. tuberculosis (39). 
Furthermore, sutezolid seemed to be superior to linezolid and tedizolid (another new 
oxazolidinone) in murine models (39, 40). Besides, sutezolid was well tolerated without 
severe side effects in small human studies (41, 42). Also tedizolid seemed to have a better 
safety profile compared to linezolid in a randomized-controlled trial of a 6-days regimen 
for bacterial skin and skin structure infections (43), and showed to be effective in the 
treatment of TB in a mouse model (40). However efficacy seemed to be less compared to 
linezolid and sutezolid. Whether the safety profiles of tedizolid and sutezolid are also bet-
ter compared to linezolid with increasing treatment duration remains to be determined. 
Besides, it might take several years before tedizolid and sutezolid will be available for 
routine use.
In conclusion, the present study in mice showed no added value of the addition of 
verapamil to a backbone of moxifloxacin and linezolid in terms of outcome after three 
months of treatment. Verapamil did prevent relapse in spleen tissue, whereas relapse in 
lung tissue could not be evaluated. Moreover, the backbone of moxifloxacin and linezolid 
showed a strong and steady CFU decline. A study performed in an MDR-TB mouse 




Specified pathogen-free female BALB/c mice were obtained from Charles River (Les On-
cins, France). At the start of the experiments, animals were 13-15 weeks old and weighed 
20-25 grams. Experimental protocols adhered to the rules specified in the Dutch Animal 
Experimentation Act and are in concordance with the EU animal directive 2010/63/EU. 
The Institutional Animal Care and Use Committee of the Erasmus MC approved the 
present protocols (117-12-14). 
experimental set-up
For treatment efficacy and pharmacokinetic analyses, a total of 99 mice (51 mice for 
efficacy assessment and 48 mice for pharmacokinetic analysis) were infected with M. 
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tuberculosis as described previously (figure S1) (44). In short, mice under anaesthesia were 
infected by intra-tracheal instillation with a suspension (40 µL) containing 2.9 x 105 
colony forming units (CFU, 2.5 – 3.2 x 105) of the Beijing VN 2002-1585 genotype 
strain (45), followed by inhalation to ensure the formation of a bilateral TB infection (44). 
Two weeks after infection, three mice were used as control to determine infection efficacy 
and reproducibility in time. 48 mice were divided in two combination therapy groups; 
group one received 200 mg/kg moxifloxacin (Bayer, Leverkusen, Germany) plus 100 mg/
kg linezolid (Sigma-Aldrich, Zwijndrecht, the Netherlands), the second group received the 
same backbone in combination with 12.5 mg/kg verapamil (Sigma-Aldrich, Zwijndrecht, 
the Netherlands). Selected doses were chosen based on previous in vivo / mouse studies 
(24, 40, 46). Dry powder moxifloxacin was dissolved in distilled water + 0.05% agarose 
using a mortar and pestle. Dry powder linezolid was dissolved in distilled water and added 
to the moxifloxacin suspension. Verapamil was dissolved in distilled water and added to 
the moxifloxacin + linezolid suspension. Drugs were administered orally for 5 times per 
week, using a feeding cannula in a total volume of 0.2 mL per day. 
mycobacterial load (efficacy) assessment
Half of the infected mice receiving treatment (n=51) were sacrificed at the start and after 
4, 8, and 12 weeks of therapy (n=3 per time point per regimen) and at 12 weeks post-
treatment to assess relapse (n=15 per regimen). To prevent carry-over of TB-drugs, therapy 
was stopped 72 hours before sacrificing the mice and activated charcoal (0.4%) was added 
to the culture media. The lungs and spleen were removed aseptically and homogenized 
in M-tubes with the gentleMACS Octo Dissociator using the RNA program (Miltenyi 
Biotec BV, Leiden, the Netherlands) in 2 mL phosphate buffered saline. From each tissue 
homogenate 10-fold serial dilutions were performed and samples of 200 μL were cultured 
on drug-free 7H10 Middlebrook agar containing activated charcoal, and incubated for 28 
days at 37°C with 5% CO2 to perform colony counting.
Pharmacokinetic analyses
Pharmacokinetic analyses were performed at steady state after 4 weeks of treatment in the 
other half of the infected mice (n=48). These mice were sacrificed by CO2 exposure and 
blood samples were taken via cardiac puncture at 0.25, 0.5, 1, 1.5, 3, 5, 10 and 24 hours 
after the dose. Three animals were euthanized for each of the eight sampling time points in 
each group (n=48 total). Blood was collected in microcentrifuge tubes containing EDTA. 
Subsequently blood was centrifuged at 10,000 xg for 5 minutes to obtain plasma, which 
was stored at -80°C upon analysis. 
Moxifloxacin, linezolid and (nor-)verapamil concentrations in plasma were analysed by 
validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/
MS) for human samples at the University Medical Centre Groningen, the Netherlands 
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(47, 48) (see Supplementary file). Assays were cross-validated for the measurement in 
murine plasma (see Supplementary file). All measured concentrations were total (i.e. 
protein-bound plus unbound) drug concentrations. Pharmacokinetic parameters were 
assessed using standard non-compartmental methods in Phoenix WinNonlin version 6.4 
(Pharsight Corporation), as described previously (49). 
statistical analysis
CFU counts were log10 transformed before analysis. Group mean CFU counts after vari-
ous time points after start of treatment were compared using one-way analysis of variance 
with a Bonferroni multiple comparison test. Proportions of mice relapsing were compared 
using the Fisher’s exact test. The statistical significance level adopted was p <0.05. Analyses 
were performed using Prism 5 (GraphPad software, San Diego, CA, USA).
Acknowledgements 




 1. WHO. Global tuberculosis report 2017. 2017.
 2. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant 
tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914.
 3. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and exten-
sively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621-9.
 4. Fattorini L, Tan D, Iona E, Mattei M, Giannoni F, Brunori L, et al. Activities of moxifloxacin alone and 
in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis 
infection in BALB/c mice. Antimicrob Agents Chemother. 2003;47(1):360-2.
 5. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant 
populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47(2):653-7.
 6. Kang YA, Shim TS, Koh WJ, Lee SH, Lee CH, Choi JC, et al. Choice between Levofloxacin and 
Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Ann Am Thorac Soc. 
2016;13(3):364-70.
 7. WHO. WHO treatment guidelines for drug-resistant tuberculosis 2016 update. 2016:7.
 8. Yang C, Lei H, Wang D, Meng X, He J, Tong A, et al. In vitro activity of linezolid against clinical 
isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant 
strains from Beijing, China. Jpn J Infect Dis. 2012;65(3):240-2.
 9. Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, et al. Systematic review and meta-analysis 
of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-
resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603-15.
 10. Chang KC, Yew WW, Tam CM, Leung CC. WHO group 5 drugs and difficult multidrug-resistant 
tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother. 
2013;57(9):4097-104.
 11. Conradie F DA, Everitt D, Mendel C, van Niekerk C, Howell P, et al. . The NIX-TB trial of pretomanid, 
bedaquiline and linezolid to treat XDR-TB.  Conference on Retroviruses and Opportunistic Infections; 
Seattle, Washington, the United States 2017.
 12. Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pre-
tomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant 
MDR-TB (ZeNix) [Internet]. clinicaltrials.gov. 2017 [cited 21February 2018]. Available from: https://
clinicaltrials.gov/ct2/show/NCT03086486.
 13. Adams KN, Szumowski JD, Ramakrishnan L. Verapamil, and its metabolite norverapamil, inhibit 
macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J 
Infect Dis. 2014;210(3):456-66.
 14. Escribano I, Rodriguez JC, Llorca B, Garcia-Pachon E, Ruiz M, Royo G. Importance of the efflux pump 
systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemo-
therapy. 2007;53(6):397-401.
 15. Te Brake LHM, de Knegt GJ, de Steenwinkel JE, van Dam TJP, Burger DM, Russel FGM, et al. The 
Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: 
Unraveling the Black Box. Annu Rev Pharmacol Toxicol. 2017.
 16. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in 
vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 
1981;41(5):1967-72.
75Additional value of verapamil
 17. Seral C, Michot JM, Chanteux H, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Influence of 
P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob 
Agents Chemother. 2003;47(3):1047-51.
 18. Coelho T, Machado D, Couto I, Maschmann R, Ramos D, von Groll A, et al. Enhancement of antibiotic 
activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from 
Brazil. Front Microbiol. 2015;6:330.
 19. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, et al. Contribution of efflux 
to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One. 
2012;7(4):e34538.
 20. Rodrigues L, Villellas C, Bailo R, Viveiros M, Ainsa JA. Role of the Mmr efflux pump in drug resistance 
in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(2):751-7.
 21. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, et al. Rifampicin 
reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. 
Am J Respir Crit Care Med. 2011;184(2):269-76.
 22. de Knegt GJ, van der Meijden A, de Vogel CP, Aarnoutse RE, de Steenwinkel JE. Activity of moxifloxa-
cin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, 
timcodar, colistin and SQ109. Int J Antimicrob Agents. 2017;49(3):302-7.
 23. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of tuberculosis 
treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med. 
2013;188(5):600-7.
 24. Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against Myco-
bacterium tuberculosis in a mouse model. Antimicrob Agents Chemother. 2015;59(1):673-6.
 25. Sotgiu G, Centis R, D’Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, et al. Efficacy, safety and 
tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and 
meta-analysis. Eur Respir J. 2012;40(6):1430-42.
 26. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively 
drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508-18.
 27. Pang Y, Lu J, Huo F, Ma Y, Zhao L, Li Y, et al. Prevalence and treatment outcome of extensively drug-
resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis 
in China: A five-year review. J Infect. 2017.
 28. Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T. Concentra-
tion-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood 
Tuberculosis: The Dynamic Duo. Clin Infect Dis. 2016;63(suppl 3):S88-S94.
 29. Zou L, Liu M, Wang Y, Lu J, Pang Y. Determination of in vitro synergy between linezolid and other anti-
microbial agents against Mycobacterium tuberculosis isolates. Tuberculosis (Edinb). 2015;95(6):839-42.
 30. Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, et al. What kinds of substrates 
show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug 
Metab Pharmacokinet. 2006;21(3):238-44.
 31. Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, et al. Evaluation of 
moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. 2011;38(4):888-94.
 32. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen con-
taining rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled 
phase 2 trial. Lancet Infect Dis. 2013;13(1):27-35.
 33. Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, et al. Comparison of 
the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-
resistant tuberculosis patients. Clin Pharmacokinet. 2010;49(8):559-65.
76 Chapter 3.2
 34. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of 
linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45(6):1843-6.
 35. Fuenmayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety and pharmacokinetics of vera-
pamil SR vs verapamil IR in hypertensive patients. Drugs. 1992;44 Suppl 1:1-11.
 36. Shand DG, Hammill SC, Aanonsen L, Pritchett EL. Reduced verapamil clearance during long-term oral 
administration. Clin Pharmacol Ther. 1981;30(5):701-6.
 37. Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, et al. Linezolid Dose That 
Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. 
Antimicrob Agents Chemother. 2017;61(8).
 38. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, et al. Moxifloxacin, ofloxacin, 
sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharma-
codynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51(2):576-82.
 39. Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, et al. In vitro and in vivo ac-
tivities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents 
Chemother. 2014;58(6):3217-23.
 40. Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, et al. Contribution of Oxazolidinones 
to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuber-
culosis. Antimicrob Agents Chemother. 2015;60(1):270-7.
 41. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, et al. Mycobactericidal activity of 
sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. 
PLoS One. 2014;9(4):e94462.
 42. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and 
whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in 
healthy volunteers. J Infect Dis. 2010;202(5):745-51.
 43. Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, et al. Analysis of the phase 3 ESTABLISH 
trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents 
Chemother. 2015;59(2):864-71.
 44. De Steenwinkel JE, De Knegt GJ, Ten Kate MT, Van Belkum A, Verbrugh HA, Hernandez-Pando R, 
et al. Immunological parameters to define infection progression and therapy response in a well-defined 
tuberculosis model in mice. Int J Immunopathol Pharmacol. 2009;22(3):723-34.
 45. de Steenwinkel JE, ten Kate MT, de Knegt GJ, Verbrugh HA, Aarnoutse RE, Boeree MJ, et al. 
Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tubercu-
losis caused by the Beijing genotype of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 
2012;56(9):4937-44.
 46. Gengenbacher M, Duque-Correa MA, Kaiser P, Schuerer S, Lazar D, Zedler U, et al. NOS2-deficient 
mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. 
Sci Rep. 2017;7(1):8853.
 47. Harmelink IMAW, A.M.; Greijdanus, B.; Uges, D.R. A rapid and simple liquid chromatography-tandem 
mass spectrometry method for the determination of linezolid in human serum. EJHP science.14:3-7.
 48. Pranger AD, Alffenaar JW, Wessels AM, Greijdanus B, Uges DR. Determination of moxifloxacin in 
human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatogra-
phy- tandem mass spectrometry method. J Anal Toxicol. 2010;34(3):135-41.
 49. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, et al. Pharmacokinet-
ics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents 
Chemother. 2010;54(3):1068-74.
77Additional value of verapamil
suPPlemenTAry fIle 1.
Moxifloxacin concentrations in plasma were analyzed with a LC-MS/MS assay, validated 
for human plasma, at the University Medical Center Groningen, the Netherlands (1). 
Crossvalidation of the assay for human plasma to murine plasma was performed by com-
paring responses of fivefold measurements of Quality Control (QC) moxifloxacin samples 
(concentrations 0.5, 2.5 and 5.0 mg/L) in human plasma with those in murine plasma 
after analysis of all samples with the LC-MS/MS assay for human plasma. The accuracy of 
measurement of murine samples with the assay for human samples was between 88-97% 
and the within-run CV amounted to 4.0-6.2%. Linezolid concentrations in plasma were 
analysed by a validated high-performance liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) assay at the University Medical Center Groningen, the Netherlands 
(2). The assay accuracy was 96.3-108.5%, the within-run CV ranged from 2.5-7.1% and 
the lower limit of quantitation (LLOQ) was 0.05 mg/L. Crossvalidation between human 
and murine plasma matrices was performed by comparing responses of three Quality 
Control (QC) linezolid concentrations (0.5, 15 and 30 mg/L in fivefold) in human plasma 
with those in murine plasma. The accuracy of murine relative to human plasma mea-
surements was between 101-114%, with a within-run CV of 1.7-2.6%. Verapamil and 
nor-verapamil concentrations were analyzed on a Thermo Fisher (San Jose, USA) triple 
quadrupole LCMS/MS with a FinniganTM Surveyor® LC pump and a FinniganTM 
Surveyor® autosampler. The mobile phase consisted of an aqueous buffer (containing am-
monium acetate 5 g/L, acetic acid 35 ml/L and trifluoroacetic anhydride 2mL/L water), 
water and acetonitrile and had a flow of 0.3 mL/min. Samples were prepared by 100 µL 
serum or plasma and 750 µL precipitation reagent (mixture of methanol and acetonitrile 
(4:21, v/v) containing cyanoimipramin as internal standard), were vortexed for 1min, 
and subsequently centrifuged at 11,000×g for 5min. From the clear upper layer 5µL was 
injected onto the LCγMS/MS system. The FinniganTM TSQ® Quantum Discovery mass 
selective detector was operating in electrospray positive ionization mode and performed 
selected reaction monitoring. The mass transitions for verapamil were 455.3 m/z  165.1 
m/z and for norverapamil 441.2 m/z- 165.0 m/z; a scan width of 0.5m/z was used. The 
calibration curves were linear within the concentration range of 18 to1800 ug/L for 
verapamil and 19 to 1900 ug/L for norverapamil; with a correlation coefficient (R2) of 
0.997 and 0.999 resp. This method was precise and accurate: within day precision ranged 
between 1.0% and 5.5% for verapamil, 1.6% to 5.9% for norverapamil and between-day 
precision ranged from 1.5% to3.1% for verapamil and 0.0% to1.2% for norverapamil. 




LZD; linezolid, MXF; moxifloxacin, PK; pharmacokinetics, TB; tuberculosis, VPM; verapamil
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ABsTrAcT
One of the reasons for the lengthy tuberculosis (TB) treatment is the difficult to treat non-
multiplying mycobacterial subpopulation. In order to assess the ability of (new) TB drugs 
to target this subpopulation, we need to incorporate dormancy models in our pre-clinical 
drug development pipeline. In most available dormancy models it takes long to create a 
dormant state and it is difficult to identify and quantify this non-multiplying condition. 
The Mycobacterium tuberculosis 18b strain might overcome some of these problems, 
because it is dependent on streptomycin for growth and becomes non-multiplying after 10 
days of streptomycin starvation, but still can be cultured on streptomycin-supplemented 
culture plates. We developed our 18b dormancy time-kill kinetic model to assess the dif-
ference in activity of isoniazid, rifampicin, moxifloxacin and bedaquiline against log-phase 
growth compared to the non-multiplying M. tuberculosis subpopulation by CFU counting 
including a novel AUC-based approach as well as time-to-positivity (TTP) measurements. 
We observed that isoniazid and moxifloxacin were relatively more potent against 
replicating bacteria, while rifampicin and high dose bedaquiline were equally effective 
against both subpopulations. Moreover, the TTP data suggest that including a liquid 
culture-based method could be of additional value as it identifies a specific mycobacterial 
subpopulation that is non-culturable on solid media. 
In conclusion, the results of our study underline that the time-kill kinetics 18b dor-
mancy model in its current form is a useful tool to assess TB drug potency and thus has its 
place in the TB drug development pipeline.
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InTroducTIon
To achieve the targets of the End TB Strategy requiring profound reductions of tubercu-
losis (TB) incidence and death rates, there is an urgent need for therapy improvement (1). 
The current treatment for drug-susceptible TB consists of a combination of TB drugs for 
at least six months (1). This prolonged duration has an unfavorable effect on treatment 
compliance and shorter regimens are therefore highly required.
One of the reasons for this lengthy treatment is the difficulty in eradicating the non-
multiplying Mycobacterium tuberculosis subpopulation (2). In the non-multiplying state 
bacteria stop dividing, lower their metabolism and thicken the cell wall in response to 
different stress conditions with an unfavorable effect on the activity of TB drugs (3). Conse-
quently, it is important to target the non-multiplying bacilli when aiming at shortening TB 
treatment duration. In order to assess the ability of (new) TB drugs to target these bacteria, 
we need to incorporate dormancy models in our pre-clinical drug-development pipeline. 
In most available dormancy models, creating a dormant state is a lengthy process (4, 5). 
In addition, it can be difficult to identify and quantify the non-multiplying mycobacterial 
subpopulation, since some of these mycobacteria are non-culturable on solid media (6, 7). 
Therefore, the 18b model could be an attractive alternative for studying TB drug potency 
against non-multiplying M. tuberculosis. The 18b strain is a clinical M. tuberculosis isolate 
obtained from a patient in Japan in 1955 (8). It belongs to clade 3 of the ancient ancestral 
lineage of the Beijing family. This strain is dependent on streptomycin for growth due 
to an insertion of a single cytosine in the 530 loop of the 16S rRNA and a single amino 
acid insertion in the N-terminal domain of initiation factor 3 (9). The advantage of this 
strain is that in the absence of streptomycin the mycobacteria stop multiplying in a short 
time-frame of approximately 10 days. After streptomycin removal, the gene expression 
is altered causing a shift in its metabolism from aerobic (high NADH-oxidase levels) to 
microaerophilic (induction of cytochrome bd-type menaquinol oxidase) allowing the cell 
to adapt to a non-multiplying state (9, 10). The up-regulation of ‘dormancy regulon’ and 
‘stationary-phase induced’ genes in this state are overall consistent with other dormancy 
models e.g.; multiple stress, phosphate depletion, nutrient depletion and hypoxia, as well 
as with the gene expression of intracellular M. tuberculosis (9). An additional advantage is 
that CFU enumeration can still be performed when 18b is plated on culture plates supple-
mented with streptomycin. Several studies have shown that liquid culture methods such as 
the most probable number (MPN) and time-to-positivity (TTP) allow the identification 
of a mycobacterial subpopulation that is non-culturable on solid media (11, 12). This 
indicates that combining solid and liquid culture methods is important for quantification 
of the total mycobacterial load present when assessing the activity of TB drugs. 
In this study we assessed the applicability of the 18b strain by comparing the activity 
of isoniazid, rifampicin, moxifloxacin and bedaquiline against both log-phase growth and 
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non-multiplying M. tuberculosis subpopulations. We performed time-kill kinetics assays, 
assessed CFUs and included a novel AUC based approach to compare drug activity against 
the non-multiplying (STR-starved) state relative to log-phase growth (STR-exposed). 
Besides we assessed the TTP by liquid culturing for STR-exposed and STR-starved 18b 
in order to optimize the detection methods for mycobacteria in different metabolic states.
resulTs
Time-kill kinetics 
STR-exposed and STR-starved 18b cultures were exposed during 6 days to 4 concentra-
tions of isoniazid, rifampicin, moxifloxacin and bedaquiline (1/25, 1/5, 1 and 5 times 
fCmax). The TB drugs were added at day 6 post inoculation to the STR-exposed cultures 
and at day 14 post inoculation to the STR-starved mycobacteria. The concentration- and/
or time-dependent activity of these four TB drugs against STR-exposed and STR-starved 
18b are shown in figure 1. Isoniazid showed time-dependent activity against both popula-
tions, with similar CFU counts for all concentrations tested after 6 days of exposure. An 
increased CFU count of STR-exposed 18b was observed at day 6 after isoniazid exposure, 
while the CFU count of STR-starved 18b dropped further. Rifampicin displayed time- 
and concentration-dependent activity against both STR-exposed and -starved 18b, with 
10 µg/ml nearly eliminating STR-starved 18b. Also moxifloxacin and bedaquiline showed 
time- and concentration-dependent activity. Interestingly, moxifloxacin concentrations of 
0.4 µg/ml and 2 µg/ml were more potent against STR-exposed 18b than 10 µg/ml, while 
in the STR-starved experiment 10 µg/ml was only slightly less active compared to 2 µg/ml. 
To affirm persistence of the streptomycin-dependent phenotype, mycobacterial growth 
of the samples that were not exposed to drugs (controls) was assessed at day 0 and day 6 on 
Middlebrook plates without streptomycin (indicating streptomycin independency) and 
compared to the CFU counts on streptomycin containing plates. In all control samples, 
only low levels of STR-independency were observed, ranging from 0.0004% at day 0 till 
0.18% at day 6 in STR-starved cultures.
To enable the comparison of the TB drug activity against STR-starved 18b relative to 
STR-exposed 18b we used the difference in AUC (AUC of the control -unexposed- curve 
minus the AUC of the TB drug exposed curve). Assessing AUC differences allows for a 
more solid comparison between TB drug activity against both mycobacterial populations 
as this method takes into account the increase in the STR-exposed control observed at 
day 6 as opposed to the rather unchanged STR-starved control at day 6 compared to day 
0. This way an overestimation of TB drug activity against the STR-starved population is 
precluded. 
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figure 1. Bactericidal activity of 0.4, 2, 10 and 50 µg/ml isoniazid (A and B), 0.08, 0.4, 2 and 10 µg/ml rifampicin 
(C and D), 0.08, 0.4, 2 and 10 µg/ml moxifloxacin (E and F) and 0.01, 0.05, 0.25 and 1.25 µg/ml bedaquiline (G 
and H) against strain 18b in STR-exposed (A, C, E and G) and STR-starved state (B, D, F and H). TB drugs were 
added at day 6 after inoculation in experiments with STR-exposed 18b and at day 14 after inoculation with STR-
starved 18b. Data are presented as one representative of two experiments. RIF, rifampicin; INH, isoniazid; MXF, 
moxifloxacin; BDQ, bedaquiline; exp, STR-exposed; strv, STR-starved. Concentrations are indicated in µg/ml.
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The mean differences in AUC between TB drug exposed and the control samples are 
reported in figure 2. Isoniazid and moxifloxacin caused a higher difference in AUC on 
STR-exposed 18b compared to STR-starved 18b, confirming that these drugs were more 
active against mycobacteria in log-phase growth, with exception of 10 µg/ml moxifloxacin, 
which showed almost no difference in AUC between both states. The activity of rifampicin 
and bedaquiline against both mycobacterial populations was generally comparable, with 
exception of the highest concentration of bedaquiline that showed more activity against 
STR-exposed 18b (figure 2). 
figure 2. Mean differences of the area under the curve of CFU data between TB drugs and the respective controls. 
RIF, rifampicin; INH, isoniazid; MXF, moxifloxacin; BDQ, bedaquiline; +, STR-exposed; -, STR-starved. Con-
centrations are indicated in µg/ml.
Time-to-positivity
We added a liquid culturing method, since this might identify an additional mycobacterial 
subpopulation which cannot be cultured on solid culture plates. To assess the TTP, the 
control (unexposed to TB drugs) culture was added to a mycobacterial growth indicator 
tube (MGIT) supplemented with streptomycin at day zero. This was repeated at day 6 
for the control culture and washed samples of all drug-exposed cultures (STR-exposed 
and –starved). The TTP was automatically recorded.
The TTP after six days of exposure to the different TB drugs is shown in figure 3. The 
control sample of the STR-exposed culture exhibited an expected decrease in TTP from 
an average of 86.5 hours to 28.5 hours. The control sample of STR-starved 18b showed 
a small increase in TTP from on average 98 hours on day zero to 129 hours on day 6 
compatible with the small decrease in CFU as observed in the time-kill kinetics assay. 
As for isoniazid activity, the same concentration independence was observed against 
both the STR-exposed and the STR-starved mycobacterial populations, except for the 
longer TTP observed at 50 µg/ml in the STR-starved population. Rifampicin, moxi-
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floxacin and bedaquiline showed concentration-dependent activity for all concentrations 
within the TTP assay, in both the STR-exposed and STR-starved states, with exception of 
10 µg/ml moxifloxacin (figure 3). 
Strikingly, the MGIT results revealed hardly any difference in TTP between the STR-
starved and STR-exposed cultures when exposed to rifampicin and isoniazid, while the 
CFU counts of the STR-starved cultures were on average 2 logs lower in the TKK assay. 
figure 3. Bactericidal activity of rifampicin, isoniazid moxifloxacin and bedaquiline against 18b assessed by the 
BACTEC MGIT through Time to Positivity (TTP). Data are shown as 2log TTP mean with range (n=2). Samples 
were taken at day 6 of the corresponding experiments. INH, isoniazid; RIF, rifampicin; MXF, moxifloxacin; BDQ, 
bedaquiline; +, STR-exposed 18b ; -, STR-starved 18b. Concentrations are indicated in µg/ml.
dIscussIon
In this in vitro study, we explored the applicability of the time-kill kinetics 18b dormancy 
model for assessment of TB drug activity against different M. tuberculosis subpopulations 
by using different detection methods. 
The observed time-dependent activity of isoniazid and concentration- and time-
dependency of rifampicin, moxifloxacin and bedaquiline in our time-kill kinetics assay 
against the active, fast multiplying state is in line with previous reports of the activity 
of these drugs against other mycobacterial strains in log-phase (13-15). This suggests 
that there is no interaction with the streptomycin added to the bacteria. The activitiy of 
isoniazid and rifampicin against STR-starved 18b is in line with our previous study as-
sessing the activity of these drugs against low metabolically active M. tuberculosis (H37Rv) 
90 Chapter 4.1
(16). This indicates that these drugs act similarly against M. tuberculosis in both slow and 
non-multiplying states.
In our study moxifloxacin concentrations of 0.4 µg/ml and 2 µg/ml showed higher 
potency against STR-exposed 18b compared to 10 µg/ml, which is comparable to a previ-
ous in vitro study of moxifloxacin against Beijing VN 2002-1585 in which maximum 
activity was reached at 0.5 µg/ml (14). This phenomenon is known as the ‘Eagle effect’ and 
was first described by Eagle et al. (17), who observed that there was less activity at higher 
exposure to penicillin for several bacteria. Interestingly, this ‘Eagle effect’ was not observed 
in experiments with STR-starved 18b nor in acid-phase and oxygen starved H37Rv in the 
hollow fiber infection model (18, 19). Surprisingly, Wu et al. did observe the ‘Eagle effect’ 
in nutrient-starved Mycobacterium smegmatis (20). However, this effect was almost absent 
when these M. smegmatis cultures were pre-treated with chloramphenicol to stop protein 
synthesis. This suggests that protein synthesis plays an important role in this phenomenon 
and might explain its absence in various dormant cultures, including our STR-starved 18b 
cultures. The ‘Eagle effect’ of moxifloxacin was also not observed in our previous in vivo 
experiments (unpublished data) or in published in vivo TB studies (21). Therefore the true 
clinical value of this effect seems even more difficult to understand. 
In this study, we introduced an AUC-based approach to compare TB drug activity 
between different mycobacterial conditions. This novel method provides additional infor-
mation to CFU counts and is central for appropriate assessment of TB drug activity on 
different subpopulations, since it corrects for the increasing STR-exposed control popula-
tion (unexposed to TB drugs), while the STR-starved control stays at similar levels. This 
knowledge is important when in the future more targeted therapy will be used for which it 
might matter whether the TB drug is more active on the non-multiplying state compared 
to log-phase growth or vice versa. In fact, although the CFU counts of the STR-starved 
M. tuberculosis exposed to isoniazid were lower compared to the STR-exposed population 
at day 6, a greater AUC difference between the control and the isoniazid-exposed samples 
was observed in the STR-exposed bacteria, confirming that isoniazid is more active on 
STR-exposed 18b compared to STR-starved, instead of equally active as might have been 
concluded based on the similar absolute CFU decline observed. As such this also serves as 
a back-validation of our adapted 18b model. Also, we were able to show that rifampicin 
displayed the most potent activity against STR-starved 18b compared to STR-exposed 
18b as there was no difference in AUC between the STR-starved and the STR-exposed 
population. Similar to isoniazid, a larger AUC difference was observed for moxifloxacin in 
the STR-exposed bacilli, except for 10 µg/ml, which might be caused by the Eagle effect 
which was more pronounced in the STR-exposed state compared to the STR-starved state. 
As a result, the difference in activity between multiplying and non-multiplying subpopu-
lations might be (artificially) reduced. The fact that the AUC differences for bedaquiline 
were similar in the lower concentrations tested should be interpreted with caution as in 
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both metabolic states almost no activity against 18b was observed. The AUC differences 
increased in the higher concentrations and it would be of interest to assess whether the 
activity against log-phase growth and non-replicating bacteria would indeed change when 
exposed for a longer period of time, as other in vitro studies reported that it takes time for 
bedaquiline to display bactericidal action (22). Overall, these findings are in line with the 
expected performances of these drugs and confirm the value of including AUC difference 
assessments in the newly developed 18b time kill-kinetics assay. 
In our study, we included TTP as a quantification method to assess the difference 
between solid and liquid culture medium for the detection of the non-culturable myco-
bacterial subpopulation. Interestingly, we observed especially for rifampicin that the TTP 
of the STR-starved cultures was on average shorter than would be expected based on the 
CFU counts. In fact, the TTP of the starved cultures exposed to rifampicin was almost 
similar to the STR-exposed cultures at all concentrations tested, while the CFU counts of 
the STR-starved treated samples were considerably lower than the STR-exposed samples 
at day 6. A possible explanation for these results might be that some of the STR-starved 
mycobacteria are not able to grow on solid media, but can be recovered in STR-containing 
liquid medium. This is comparable to what has been observed in vitro in non-multiplying 
M. tuberculosis cultures which could not be cultured on solid media but where growth was 
observed in liquid media even without addition of resuscitating promoting factors, when 
using the most probable number as quantification method (12). Also, in human sputum 
samples a non-multiplying subpopulation was detected when comparing CFU counts to 
TTP measurements during treatment (11). Therefore, the TTP assay might give a better 
estimation of the total mycobacterial load and thus should be performed in addition to 
classical CFU counting. 
The observed drug activity of rifampicin, moxifloxacin and bedaquiline in our study 
was comparable to previous 18b studies (10, 23). These studies were generally based on 
the resazurin microplate assay (REMA) and luciferase for mycobacterial load assessments 
as opposed to the time-kill kinetics assay and CFU counting as used in the present study. 
Although these assays are relatively easy to perform they cannot be used for the evaluation 
of the activity of cell wall inhibitors (23). This might explain why in these REMA and 
luciferase studies hardly any effect of isoniazid on STR-starved 18b was observed, while 
we found a 3 log CFU/ml decrease after 6 days of treatment (23, 24). The reason that 
these assays cannot be used for the assessment of cell wall inhibitors might be that the 
increase in cell wall permeability allows for a more efficient conversion of resazurin in 
resorufin, which will cause an increase in fluorescence instead of the expected decrease 
(25). This limitation is very relevant as cell wall inhibitors could be valuable components 
of short-course TB drug regimens (26), underlining the significance of the ability to assess 
the activity of this class of drugs in our adapted 18b model. Besides, REMA is an endpoint 
analysis and not applicable to time-course investigations and, although with the luciferase 
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assay time-course investigation is possible, when drugs display autofluorescence the lumi-
nescence signal is extinguished and impacts results (23). Therefore, as described in this 
paper time-kill kinetics assays with CFU counting including the use of AUC differences 
as well as TTP measurements are useful additions to the REMA and luciferase assays in 
the assessment of drug activity against the 18b strain. 
A review of Iacobino et al. showed the diversity in activity of several TB drugs in 
different dormancy models (27). Our time-kill kinetics results are most comparable to the 
results obtained in the hypoxic model of Wayne (27), which is in line with the compa-
rable gene expression profiles observed in the STR-starved state in 18b and the hypoxia 
model (9). An explanation for the differences in TB drug response between the dormancy 
models might be that every model uses a different stress condition to lower mycobacterial 
metabolism, e.g. nutrient starvation, hypoxia and a low pH, which might be associated 
with different mycobacterial phenotypes and response upon TB drug exposure (9, 27). 
Consequently it is important to use different dormancy models in the assessment of TB 
drug activity in order to mimic the heterogeneity of the non-replicating mycobacterial 
subpopulation present in TB patients. Besides, our study also confirmed the importance 
of incorporating more read outs (solid and liquid culturing), to be able to identify phe-
notypically diverse mycobacterial subpopulations. The advantages of the 18b dormancy 
model compared to other models are that the non-multiplying state can be achieved in 
only 10 days, while it takes for example 6 weeks in the nutrient starvation model and 
100 days in the 100-day stationary-phase model (4, 28). Furthermore it is more easy to 
maintain the dormancy conditions compared to hypoxia models in which sampling and 
manipulating the samples requires additional measures to maintain the hypoxic state (5). 
As such, the 18b dormancy model in its current form can be a useful tool in the early 
phase of the drug development pipeline. 
An important limitation of the 18b strain is the occurrence of STR-independent 
growth. This effect appeared to be limited in the time frame of our study. However, during 
our subsequent hollow fiber infection model (HFIM) experiments when mycobacterial 
cultures were unexposed to streptomycin during 4 weeks, complete STR-independency 
was observed and the amount of non-multiplying bacteria declined fast and became there-
fore unusable (data not shown). The decline of the non-multiplying population was also 
observed in other HFIM studies (19, 29). Therefore, the 18b strain can only be used in 
short-course experiments including the time-kill kinetics assay as described in the present 
study. 
In summary, our results confirm the differences in activity of the different TB drugs 
against the active and non-multiplying state that were expected, based on the working 
mechanisms of these drugs (30, 31). As such, our model is ‘back validated’ as a useful 
preclinical model to assess the activity of new compounds, where the mode of action and 
expected effect on the non-multiplying state is not as clear. In addition, our results support 
9318b dormancy model 
the use of classical CFU counting as well as measurement of AUC differences and TTP in 
the analyses of drug activity against 18b.
mATerIAls And meThods
Bacterial strain and growth conditions
Frozen M. tuberculosis 18b samples were thawed and grown in Middlebrook 7H9 broth 
(Difco laboratories, Detroit, MI, USA), supplemented with 10% oleic acid-albumin-
dextrose-catalase enrichment (OADC, Becton Dickinson and Company (BD), Sparks, 
MD, USA), 0.5% glycerol (Scharlau Chemie S.A, Sentmenat, Spain), 0.05% Tween 80 
(Sigma Chemical co., St Louis, MO, USA) and 50 µg/ml streptomycin for actively grow-
ing 18b, under shaking conditions at 96 rpm at 37°C. For STR-starved 18b cultures no 
streptomycin was added to the broth. Cultures on solid media were grown on Middle-
brook 7H10 agar (Difco), supplemented with 10% OADC, 0.5% glycerol and 50 µg/ml 
streptomycin for 28 days at 35°C with 5% CO2.
Antimicrobials 
Isoniazid, rifampicin, moxifloxacin and streptomycin were all purchased from Sigma 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Bedaquiline was kindly provided by 
Janssen Pharmaceuticals (Johnson and Johnson, Belgium). All dry powder drugs were 
dissolved in Middlebrook broth, with the exception of rifampicin, which was first dis-
solved in dimethyl sulfoxide (DMSO). As to antimicrobial stability, 50% degradation in 
Middlebrook medium has been observed after 14 and 7 days for isoniazid and rifampicin, 
respectively (32, 33). Given the fact that the MGIT liquid culture system using the same 
broth and incubation time (6 days) is an FDA approved method for susceptibility test-
ing of isoniazid and rifampicin, we consider that the stability of those drugs during our 
time-kill kinetics assay is not a major concern. Moxifloxacin and bedaquiline have been 
shown to be stable during at least 25 days and 14 days, respectively (34, 35). Streptomycin 
showed a minor activity loss after 4 weeks (32). Since in our study, mycobacteria were only 
exposed to streptomycin for a maximum of 12 days, we assumed the impact of the activity 
loss to be limited.
Time-kill kinetics assay
TB drugs were added at day 6 post inoculation (log-phase growth) in STR-exposed experi-
ments and at day 14 post inoculation (non-multiplying) in the STR-starved experiments. 
The cultures were exposed to TB drugs for 6 days at 37 °C under shaking conditions at 96 
rpm. In the absence of TB drugs, the STR-exposed mycobacterial population increased 
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from mean log 6.7 (range 6.5-6.8) to mean log 8.3 (range 8.2-8.3) CFU/ml. As expected, 
the STR-starved population did not increase.
TB drug concentrations were based on the peak free serum concentration (fCmax); 
1/25, 1/5, 1 and 5 times fCmax. On day 0, 1, 4 and 6 after the addition of TB drugs, 
samples were taken, centrifuged at 14000 xg and washed to avoid carry over, serially 
diluted and plated onto Middlebrook plates supplemented with 50 µg/ml streptomycin. 
To affirm persistence of the streptomycin-dependent phenotype, mycobacterial growth 
of the unexposed control sample was assessed at day 0 and day 6 on Middlebrook plates 
without streptomycin. Results were depicted as log reduction in mycobacterial load over 
time as well as difference between the area under the curve (AUC). The AUC of the 
non-TB drug exposed 18b curves (controls) was determined based on CFU counts from 
0-6 days and was subtracted by the AUC of TB drug exposed 18b samples. In this way we 
corrected for the inherent difference between the mycobacterial load of the STR-exposed 
and STR-starved control at day 6 allowing for a solid comparison between the activity of 
TB drugs on STR-exposed and STR-starved 18b.
Time to positivity
At day zero, 200 μl of the control culture was added to a mycobacterial growth indicator 
tube (BBL MGIT; Becton, Dickinson and Company, MD, USA) in combination with 
800 μl OADC enrichment, supplemented with 50 µg/ml of streptomycin. This was re-
peated at day 6 with 200 μl of the control culture and washed samples of all drug-exposed 
cultures (STR-exposed and –starved). Tubes were incubated in the BD BACTEC™ MGIT™ 
960 automated mycobacterial detection system (Becton, Dickinson and Company, MD, 
USA) and TTP was automatically recorded and depicted as 2log TTP.
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ABsTrAcT
By improving the translational value of preclinical models, more successful and focussed 
research to shorten the treatment duration of tuberculosis can be performed. Although 
the hollow fibre infection model (HFIM) is considered to be a valuable addition to the 
drug development pipeline, its exact role is not fully determined yet. As increasing the 
dose of rifamycins is being evaluated for its treatment shortening potential, additional in 
vitro modelling is of importance. Therefore we assessed increased dosing of rifampicin and 
rifapentine in our HFIM to gain more insight into the place of the HFIM in the drug 
development pipeline. 
Total and free-fraction concentrations corresponding to daily dosing of 2.7, 10 and 50 
mg/kg rifampicin as well as 600 mg and 1,500 mg rifapentine were assessed in our HFIM 
using the Mycobacterium tuberculosis H37Rv strain. Drug activity and emergence of drug 
resistance were assessed by CFU counting and subsequent mathematical modelling over 
14 days, and pharmacokinetic exposures were checked. 
Increasing rifampicin exposure above what is expected with the standard dose did not 
result in higher antimycobacterial activity. For rifapentine, only the highest concentra-
tion showed increased activity but clinical relevance of this observation is questionable. 
Moreover, the emergence of resistance to both drugs was unrelated to exposure.
In conclusion, in the most simplistic experimental set-up, the results of the HFIM 
did not fully correspond to pre-existing clinical data. Including additional parameters 
and read-outs in this pre-clinical model could be of interest for proper assessment of the 
translational value of the HFIM. 
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InTroducTIon
Tuberculosis (TB) treatment is long and complex, leading to poor adherence, with 
emergence of drug resistance and low treatment success rates as a result. To shorten TB 
treatment duration it is important to focus on drug discovery, dose optimization and 
implementation of new drug combinations. Besides, it is necessary to improve the clinical 
predictability of pre-clinical models, to make this process more effective. This became ap-
parent in the REMoxTB trial, aimed to shorten the treatment duration of drug-susceptible 
tuberculosis from 6 to 4 months by replacing ethambutol or isoniazid for moxifloxacin 
(1). Although previous in vitro and in vivo studies showed promising results, this new 
combination lacked the expected treatment shortening potential (2-5). 
To further accelerate the improvement and development of preclinical models several 
international consortia have been established (6, 7). These consortia focus on the (back-) 
validation of pre-clinical models (both existing and new models) against the performance 
in clinical trials (6). They aim to develop an optimal research path by combining different 
preclinical models including pharmacokinetics/pharmacodynamics (PK/PD) modelling 
and a simulation framework to facilitate prediction of optimal drug combinations for 
assessment in clinical studies (6, 7).
A well-known PK/PD model is the hollow fibre infection model (HFIM). This method, 
approved by the European Medicines Agency (EMA), is developed to simulate human PK 
dynamics in vitro, while on every desired moment PD sampling of a liquid Mycobacterium 
tuberculosis culture can be performed (8). This is an improvement over traditional in vitro 
methods as for example the time-kill-kinetics (TKK) assay assessing only static TB drug 
concentrations (9). Furthermore, the HFIM allows better control of the PK profile and 
more frequent PK/PD sampling than can be performed in in vivo experiments for both 
practical as ethical reasons. Although the HFIM showed to be valuable in the assessment 
of PK/PD indices (10), its exact role in the pre-clinical drug development pipeline is not 
fully determined yet. 
For treatment improvement, dosing optimization of old as well as new TB drugs is 
gaining more interest (11, 12). Although rifampicin has been the cornerstone of TB-
treatment since decades, its optimum dose is still unknown (11, 12). Since its introduction 
in 1971, rifampicin is given to patients as a 10 mg/kg dose, while this dose is presumed to 
be mainly based on fear for adverse events and price issues, instead of proper dose-finding 
studies (13). Already in 1980 a study evaluating different doses of rifampicin (5, 10 and 20 
mg/kg) in a small population showed that increasing the rifampicin dose resulted in faster 
decline in colony forming units (CFU) during the first two days of treatment (14). Later 
in vitro and in vivo studies confirmed that increasing the rifampicin dose resulted in more 
activity and efficacy (15, 16). These observations led to the start of several clinical trials 
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assessing increased rifampicin dosing, which were all suggestive of a positive dose-response 
relationship (11, 12, 17). 
Rifapentine, approved by the FDA in 1998, has a longer half-life time and a lower 
minimum inhibitory concentration (MIC) for M. tuberculosis than rifampicin (18) and 
was primarily intended to be used for intermittent therapy to lower the patients pill load 
(19). Later, both daily dosing, and increasing the standard 600 mg dose were explored in 
order to shorten TB treatment duration, both with promising results (20-22). 
In this work we assessed the activity of standard and high dosing of rifampicin and 
rifapentine in our HFIM. We developed a PD model describing the observed change in 
CFU over time to test the effects of different dosages. We compared the results to other in 
vitro and in vivo studies as well as clinical trials, all in order to gain more insight into the 
place of this HFIM in the pre-clinical drug development pipeline.
mATerIAls And meThods
strain
Experiments were performed using the H37Rv strain, with an MIC of 0.5 mg/L for 
rifampicin and 0.125 mg/L for rifapentine. MICs were determined according to CLSI 
standards (23). Stock cultures were stored at -80°C, thawed at the start of experiments and 
incubated at 37°C for 5 days in Middlebrook 7H9 broth (Difco laboratories, Detroit, MI, 
USA), supplemented with 10% oleic acid-albumin-dextrose-catalase enrichment (OADC, 
Becton Dickinson and Company (BD), Sparks, MD, USA), 0.5% glycerol (Scharlau 
Chemie S.A, Sentmenat, Spain) and 0.05% Tween 20 (Sigma Chemical co., St Louis, 
MO, USA) under shaking conditions to facilitate log-phase growth prior to inoculation 
in our HFIM.
Antimicrobials
Rifampicin (Sigma-Aldrich, St. Louis, MO, USA) and rifapentine (Sanofi Aventis, Frank-
furt, Germany) were both dissolved in dimethyl sulfoxide (DMSO) and further diluted 
in broth to the desired concentration. Both free and total concentrations of the drugs 
were assessed in the HFIM. Rifampicin and rifapentine protein binding in human plasma 
of 80% and 97%, respectively were used to calculate the free drug concentrations (24). 
Target maximum concentrations (Cmax) were based on results of previous clinical studies 
(11, 21). The doses simulated in the HFIM were 2.7, 10 and 50 mg/kg rifampicin and 
600 mg and 1500 mg rifapentine (table 1). For rifapentine, no weight based dosage was 
chosen, since weight does not influence its plasma concentrations (21).
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hollow fibre infection model
Twenty mL samples of M. tuberculosis log-phase growth cultures (density ~2x106 CFU/
mL) preconditioned with 7H9 broth at 37°C were inoculated in the peripheral compart-
ment of the hollow-fibre cartridge (C3008 Medium Cellulosic Cartridge 5kd, FiberCell 
systems, New Market, USA). These cartridges consist of a peripheral compartment with 
inside semi-permeable hollow fibres with pores that allow drugs and nutrients to freely 
transfer in and out of the peripheral compartment, while keeping the M. tuberculosis 
in the peripheral compartment. Twenty-four hours after the cartridges were inoculated, 
the mycobacteria in each cartridge were exposed to different q24h dosing schemes of 
rifampicin or rifapentine during 14 days (table 1), at the same time one cartridge was 
unexposed to drugs and served as a control. All experiments were performed in duplicate.










2.7 mg/kg 0.74 4.19
10 mg/kg 2.00 11.34 10.00* 60.28*
50 mg/kg 10.00* 60.28* 50.20 286.70
Rifapentine
600 mg 0.47 7.60 15.70 257.40
1500 mg 0.99 14.80 33.00 544.30
*same experiment
Drugs were administered by digitally controlled syringe pumps (World Precision instru-
ments, Sarasota, Florida, USA ) through a dosing port just before the central compart-
ment, simulating the absorption rate of the drugs in humans (table 2) (24). By use of 
digitally controlled peristaltic pumps (Watson-Marlow, Cornwall, United Kingdom) fresh 
broth was pumped into the afferent port of the central compartment of the cartridge 
while drug-containing broth was iso-volumetrically removed from the efferent port of 
the system at rates programmed to simulate the half-life time of the drugs encountered in 
humans (table 2) (24). 
Table 2. Pharmacokinetic parameters
Rifampicin Rifapentine
Volume (L) 0.349 0.349
Half-life (hours) 3 16
Tmax (hours) 2 4
Protein binding (%) 80 97
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PD samples (1 mL) were collected from each cartridge just before drug administration at 
day 0, 1, 2, 3, 6, 8, 10, 13 and 14. To prevent drug carryover samples were washed and 
serially diluted as described previously (25), before adding 200 µL on solid culture plates. 
All cultures were plated on 7H10 agar plates with and without 4 mg/L rifampicin or 1 
mg/L rifapentine (4 times the clinical breakpoint), in order to assess total and resistant 
populations, respectively (26).
Pharmacokinetic assessment
Pharmacokinetic profiles of the TB-drugs to which the mycobacteria were exposed in the 
HFIMs were validated by sampling the afferent port of the central compartment leading 
to the cartridges of each HFIM twice per experiment (one week in between sampling) at 
0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours for rifampicin and at 0, 1, 2, 3, 4, 5, 8, 
12 and 24 hours for rifapentine. Samples were frozen at -80°C until further analysis.
A bio-assay was performed to assess the drug concentrations of rifampicin and rifap-
entine in the HFIM (27). Sarcina lutea was grown on blood agar plates (BD, Vianen, the 
Netherlands) during 48 hours at 35°C. Subsequently a suspension of 0.5 McFarland was 
made and plated on Mueller Hinton II plates (BD, Vianen, the Netherlands) in which wells 
with a diameter of 0.5 cm were punched. To create a standard curve, 100 µL of thawed 
known concentrations of rifampicin or rifapentine (8-4-2-1-0.5-0.25-0.125 µg/mL) were 
added in duplicate to the wells of the agar. In addition, 100 µL of each thawed HFIM PK 
sample was added to the other wells in the agar (samples were diluted when necessary). Plates 
were incubated for 24 hours at 35°C. The next day the inhibition zones of the standard 
concentrations were measured and a standard curve was made. The inhibition zones of the 
PK samples were measured and correlating concentrations were calculated based on the 
formula of the standard curve. With the same bio-assay the inhibition zones of rifapentine 
in the presence and absence of OADC were assessed with a standard curve of the previously 
described seven known concentrations, in order to assess any protein binding in the HFIM.
modelling and statistics
The CFU data were analysed by developing a semi-mechanistic nonlinear mixed-effects 
model describing the change in total and resistant colony counts over the 14 days in the 
HFIM. Data from all experiments were analysed jointly and the structure of the model 
was inspired by previous work with TKK data (28). Since estimating both the number of 
resistant bacteria in the inoculum and the delay in growth of resistant bacteria would lead 
to identifiability issues, the number of resistant bacteria in the inoculum was fixed to 10-6 
times the number of wild-type bacteria in the inoculum. The growth rate for the wild-type 
and resistant bacteria was assumed to be the same. Random inter-experiment variability 
was assumed to follow log-normal distributions. The effect of different rifamycin concen-
trations was tested on the kill-rate of the wild-type bacteria and the delay in start of growth 
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of resistant bacteria. Initial evaluation simply tested a difference between the arms (with 
different target Cmax levels), while full dynamic concentration-effect relationships could be 
evaluated. The statistical significance was assessed with likelihood ratio tests using a 5% 
confidence level. 
Plotting of the raw CFU data, PK analyses and AUC calculations was performed us-
ing Prism 5 (GraphPad software, San Diego, CA, USA). Modelling, data management, 
graphical evaluation and post processing of results were performed in R (Foundation for 
Statistical Computing, Vienna, Austria), partially using the Xpose package (Department 
of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden). The model was de-
veloped in NONMEM 7.4 (Icon Development Solutions, Ellicott City, Maryland, USA), 
aided by PsN (Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, 
Sweden) and Pirana (Pirana Software & Consulting, San Francisco, USA) (29).
resulTs
The observed rifampicin and rifapentine Cmax and total exposure (AUC(0-24h)) of all doses 
tested are shown in table 3. The measured values agreed well with the (pre-set) targets for 
all dose levels. The presence of OADC did not change the inhibition zones of rifapentine 
in our bio-assay, suggesting that protein binding does not affect rifamycin activity in the 
HFIM (data not shown).










2.7 mg/kg 0.69 (0) 3.29 (0.13)
10 mg/kg 1.82 (0.08) 10.94 (0.77) 11.30 (0.45)* 62.61 (2.44)*
50 mg/kg 11.30 (0.45)* 62.61 (2.44)* 54.48 (2.80) 312.30 (31.60)
Rifapentine
600 mg 0.50 (0.08) 7.71 (0.97) 15.27 (0.83) 240.00 (8.92)
1500 mg 1.00 (0.10) 14.64 (3.54) 33.18 (2.02) 496.20 (37.41)
*same experiment
The CFU count of the control (unexposed) cultures did not increase over time, while dur-
ing the experiment turbidity within the cartridges increased indicating bacterial growth, 
and during the last two days (days 13 and 14) even aggregation was observed. Mycobacte-
rial killing and regrowth over 14 days of exposure to rifampicin or rifapentine are shown 
in figure 1a and 1c, respectively. Exposure to both rifamycins did not result in culture 
negativity at all concentrations tested. As for rifampicin, the lowest concentration resulted 
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in less bactericidal activity compared to the other concentrations reaching a mean of 3.5 
log CFU/mL on day 10 and a mean of less than 2 log CFU/mL on day 8, respectively. 
Regarding rifapentine, the highest rifapentine concentration resulted in more bactericidal 
activity compared to the three lower concentrations at all time-points. Emergence of drug 
resistance was observed from day 6 onwards for rifampicin and from day 8 for rifapentine, 
resulting in regrowth (figure 1b and 1d). The emergence of resistance in the control cul-
tures remained below 1.3 log CFU/mL.
figure 1. Activity and emergence of resistance of different simulated daily dosing of rifampicin and rifapentine 
(intended maximum concentrations are indicated in the legend) during 14 days towards initial log-phase growth 
H37Rv in the hollow fibre infection model (n = 2, mean ±range). A) Rifampicin activity. B) Emergence of resis-
tance during rifampicin exposure. C) Rifapentine activity. D) Emergence of resistance during rifapentine exposure.
The model developed to describe total (T) and resistant (R) colony counts over time (t) 
included two separate compartments, one for wild-type (WT) and one for drug resistant 





































































































The model developed to describe total (T) and resistant (R) colony 
counts over time (t) included two separate compartments, one for 
wild-type (WT) and one for drug resistant bacteria. The inoculum (I) 
for the WT and R compartments were defined as 
𝐼𝐼𝑊𝑊𝑊𝑊 = 10𝑊𝑊𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐼𝐼𝑊𝑊𝑊𝑊×𝑒𝑒𝑒𝑒𝑒𝑒(𝜂𝜂𝐼𝐼) 
𝐼𝐼𝑅𝑅 = 𝐼𝐼𝑊𝑊𝑊𝑊 × 10−6 
where TVlogIWT is the typical WT inoculum on the log scale and ηI is the 
random inter-experiment variability drawn from a normal distribution 
with mean 0 and estimated variance ωI2. The maximal carrying 
capacity of the system (Nmax), limiting the growth rate of the bacteria, 
was set to the total inoculum (IWT + IR) given that no growth was 
observes in the control arms. The growth rate was defined as 
𝑘𝑘𝑘𝑘(𝑡𝑡) = 𝑘𝑘𝑘𝑘𝑏𝑏𝑏𝑏𝑏𝑏𝑒𝑒
(𝑁𝑁𝑚𝑚𝑏𝑏𝑒𝑒 −𝑊𝑊𝑊𝑊(𝑡𝑡) − 𝑅𝑅(𝑡𝑡))
𝑁𝑁𝑚𝑚𝑏𝑏𝑒𝑒
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of the bacteria, was set to the total inoculum (IWT + IR) given that no growth was observes 
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The model developed to describe total (T) and resistant (R) colony 
counts over time (t) included two separate compartments, one for 
wild-type (WT) and one for drug resistant bacteria. The inoculum (I) 
for the WT and R compartments were defined as 
𝐼𝐼𝑊𝑊𝑊𝑊 = 10𝑊𝑊𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐼𝐼𝑊𝑊𝑊𝑊×𝑒𝑒𝑒𝑒𝑒𝑒(𝜂𝜂𝐼𝐼) 
𝐼𝐼𝑅𝑅 = 𝐼𝐼𝑊𝑊𝑊𝑊 × 10−6 
where TVlogIWT is the typical WT inoculum on the log scale and ηI is the 
random inter-experiment variability drawn from a normal distribution 
with mean 0 and estimated variance ωI2. The maximal carrying 
capacity of the system (Nmax), limiting the growth rate of the bacteria, 
was set to the total inoculum (IWT + IR) given that no growth was 
observes in the control arms. The growth rate was defined as 
𝑘𝑘𝑘𝑘(𝑡𝑡) = 𝑘𝑘𝑘𝑘𝑏𝑏𝑏𝑏𝑏𝑏𝑒𝑒
(𝑁𝑁𝑚𝑚𝑏𝑏𝑒𝑒 −𝑊𝑊𝑊𝑊(𝑡𝑡) − 𝑅𝑅(𝑡𝑡))
𝑁𝑁𝑚𝑚𝑏𝑏𝑒𝑒
 
where the kg(t) is the growth rate at time t and kgbase is the growth rate in the unlimited 




where the kg(t) is the growth rate at time t and kgbase is the growth 
rate in the unlimited state (T << Nmax). The dynamics of the amounts of 
WT and R bacteria in the system was described by 
𝑑𝑑𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑𝑡𝑡 = 𝑘𝑘𝑘𝑘(𝑡𝑡) × 𝑑𝑑𝑑𝑑(𝑡𝑡) − 𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘 × 𝑑𝑑𝑑𝑑(𝑡𝑡) 
{
𝑡𝑡 ≤ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑡𝑡ℎ𝑒𝑒𝑒𝑒 𝑑𝑑𝑑𝑑
(𝑡𝑡)
𝑑𝑑𝑡𝑡 = 0
𝑡𝑡 > 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑡𝑡ℎ𝑒𝑒𝑒𝑒 𝑑𝑑𝑑𝑑(𝑡𝑡)𝑑𝑑𝑡𝑡 = 𝑘𝑘𝑘𝑘(𝑡𝑡) × 𝑑𝑑(𝑡𝑡)
 
Where kkill is the kill rate and DELAY is the delay in starts of growth in 
the resistant population. The total observed CFU (T) was simply WT+R.  
The kkill was found to differ between the lowest rifampicin exposure 
(Cmax 0.74 mg/L) and the other arms (p < 0.005). No additional effect 
was seen at higher rifampicin exposures. The kkill was not statistically 
different between the three lower levels of rifapentine, but some 
additional effect was seen for the highest exposure (Cmax 33 mg/L, p < 
0.005). An exposure effect on the delay in growth of the resistant 
population could not be reliably estimated for either drug. 
The parameters in the final model were all estimated with good 
precision and are listed in Table 4. The model described the observed 
data well as illustrated by the visual predictive check included in Figure 
2. The estimated growth rate of the unexposed mycobacterial 
population translated to a doubling time of 22.6 hours, which is in line 
with what is expected for M. tuberculosis (30). The model structure 
relied on certain assumptions, e.g. that there is a pre-existing small 
population of drug resistant bacteria and that the start of growth in 
this population is delayed. Alternatively one could for example assume 
no pre-existing resistant population, that the first resistant bacteria 
appear during the experiment and starts growing from that moment. 
This structure could probably also describe the data and would likely 
give the same results in terms of the drug effect evaluation. Both 
Where kkill is the kill rate and DELAY is the delay in starts of growth in the resistant 
population. The total observed CFU (T) was simply WT+R. 
The kkill was found to differ between the lowest rifampicin exposure (Cmax 0.74 mg/L) 
and the other arms (p < 0.005). No additional effect was seen at higher rifampicin expo-
sures. The kkill was not statistically different between the three lower levels of rifapentine, 
but some additional effect was seen for the high st exposure (Cmax 33 mg/L, p < 0.005). 
An exposure effect on the delay in growth of the resistant population could not be reliably 
estimated for either drug.
The parameters in the fin l model we e all estimat d with good precision and are listed 
in Table 4. The model described the observed data well as illustrated by the visual predic-
tive check included in Figure 2. The estimated growth rate of the unexposed mycobacterial 
Table 4. Final parameter estimates including uncertainty (relative standard error, RSE)
Parameter (unit) RSE
Typical values
Inoculum wild type, logIWT (log10 CFU) 6.63 1.7%
DELAY RIF (days)a 4.94 21%
DELAY RPT (days)a 4.37 21%
Growth rate, kgbase /h 0.0307 11%
Kill rate, kkill RIF /h 0.0555 6.0%
Kill rate, kkill RPT /h 0.0761 6.5%
Extra kill RIF Cmax > 0.74 mg/Lb 0.631 16%
Extra kill RPT Cmax > 15.7 mg/Lb 0.264 32%
Inter experiment variability CV%
Inoculum wild type, logIWT (log10 CFU) 107% 19%
DELAY RIF 43% 22%
DELAY RPT 20% 73%
Kill rate, kkill RIF /h 7.8% 23%
Kill rate, kkill RPT /h 0 FIX
Residual variability (Proportional error) 16.4% 9%
a Estimated through the MTIME parameter in NONMEM
b Parameterized as kkill high rifamycin = kkill*(1+ Extra kill high rifamycin)
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population translated to a doubling time of 22.6 hours, which is in line with what is 
expected for M. tuberculosis (30). The model structure relied on certain assumptions, e.g. 
that there is a pre-existing small population of drug resistant bacteria and that the start 
of growth in this population is delayed. Alternatively one could for example assume no 
pre-existing resistant population, that the first resistant bacteria appears during the experi-
ment and starts growing from that moment. This structure could probably also describe 
the data and would likely give the same results in terms of the drug effect evaluation. Both 
structures make sense theoretically, but with the information at hand we have no chance 
to discriminate which is the better. 
figure 2. Visual predictive check of the final model. The blue rings represent the observed data, the red dashed 
line is the median of the observed data, the black line in the median model prediction and the grey area is the 90% 
confidence interval of the predicted median. 
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dIscussIon
In the present study higher rifampicin exposure did not result in increased antibacterial 
activity, not even at extremely high concentrations. In line, increased activity was only 
observed for the highest rifapentine concentration, which is probably not representative 
for what can be reached in TB patients considering the high protein binding of rifapentine 
as well as the reported relation between high exposure and drug intolerance (31, 32). 
The reason for choosing these high rifamycin concentrations was to compensate for the 
expected protein binding in the HFIM. However, it was subsequently shown that protein 
binding did not play a significant role in vitro. This is an important finding and should 
be considered when interpreting the relation between rifampicin exposure and activity in 
other in vitro studies. In our study the (concentration independent) emergence of rifamy-
cin resistance appeared to be the limiting factor for further CFU decrease after 6 days of 
mono-exposure. This is not expected to impact clinical efficacy as in patients, rifamycins 
are always combined with other antimicrobial agents. Previous HFIM studies also failed to 
show an exposure response relationship for rifampicin (33, 34) and to our knowledge, no 
other HFIM experiments with rifapentine have been described. Interestingly and similar 
to the present study, in those studies simulated high rifampicin dosages (ranging from 
100-900 mg) were not enough to reach sterilization (33, 34). 
These findings in the HFIM are in contrast to the results observed in our in vitro time-
kill curves where no CFUs were detectable after 6 days of exposure to 8 mg/L rifampicin 
(35, 36), while this concentration has a lower Cmax and AUC0-24 compared to the highest 
given dose in the current study. The same holds true for rifapentine, as in our previous 
time-kill experiments with the M. tuberculosis Beijing-1858 strain rifapentine showed 
concentration and time-dependent activity, with 4 mg/L resulting in sterilising activity 
(unpublished results). It could be hypothesized that this discrepancy is due to the presence 
of a mycobacterial subpopulation with lower metabolic activity in our HFIM compared 
to time-kill experiments given the significantly longer duration of HFIM experiments. 
Our previous time-kill studies of rifampicin showed that rifampicin activity was lower 
in low-metabolically active M. tuberculosis, which was associated with the emergence of 
drug resistance (35, 36). In line, Hu et al. showed that 16-fold higher concentrations of 
rifampicin were required to eradicate stationary phase growth cultures compared to log 
phase growth cultures (16, 36). Therefore, the presence of such a population in our HFIM 
might explain the reduced bactericidal activity observed in our HFIM compared to our 
time-kill experiments.
Previous in vivo studies on rifampicin and rifapentine did show that increasing the dose 
in M. tuberculosis infected mice resulted in higher efficacy (15, 37). Our group showed that 
an eight-fold increase in the standard rifampicin dose of 10 mg/kg allowed a treatment 
reduction from 6 to 2 months in a murine TB model (15). In addition, Rosenthal et al. 
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showed that when the rifampicin dose was increased to 40 mg/kg no relapse of infection 
was observed after 12 weeks of treatment in TB infected mice (versus 100% of the mice 
treated with the standard dose) (37). The same study showed dose dependant efficacy with 
doses up to 20 mg/kg rifapentine in combination with standard dosing of isoniazid and 
pyrazinamide (37). Generally, clinical studies were also suggestive of an exposure-response 
relationship for both rifamycins. Several studies in TB patients showed less early bacteri-
cidal activity (EBA) with low dosing of rifampicin (5 mg/kg) compared to the standard 
dose of 10 mg/kg (14, 38, 39). Which is comparable to our HFIM results, confirming 
that lower rifampicin exposure is indeed associated with lower success rates. However, 
two of these studies also showed an increased EBA of rifampicin when a 20 mg/kg dose 
was used (14, 39). Also studies assessing doses up to 35 mg/kg rifampicin were suggestive 
for increased effectivity of high rifampicin dosing when liquid culturing was applied (11, 
40). For rifapentine an exposure-response relationship was shown when combining the 
results of the liquid cultures of two phase 2 trials assessing daily dosing ranging from 
10-20 mg/kg and 450-1500 mg (21). However, whether these clinical observations would 
indeed lead to improved cure is still to be determined as only surrogate markers as time 
to culture conversion were used and the clinical follow up was maximum 12 months (17, 
22, 40). It could be speculated that the discrepancy between these studies and our results 
might be caused by various factors present in in vivo models as well as in TB patients 
influencing rifamycin efficacy, which are absent in our HFIM. One could think of the 
presence of intracellular mycobacteria, variability in mycobacterial subpopulations, as well 
as different immunological factors and differences in drug tissue penetration. The clinical 
predictability of the HFIM might therefore be increased by including more metabolic 
populations (41), the use of macrophages (42) and other intra-cellular approaches (43) as 
well as different mycobacterial strains (18). 
A remarkable observation is that results of liquid cultures as used in clinical trials were 
suggestive for increased efficacy of both rifamycins, whereas the results of solid cultures 
were less conclusive (11, 21, 40). It could be speculated that increased effect of higher 
exposure to the rifamycins is due to the effect on a mycobacterial subpopulation which is 
better detectable in liquid media. Given the fact that in the present study mycobacterial 
cultures were grown on solid media, this subpopulation might have been missed and thus 
an additional explanation for the lack of concentration dependent activity of rifamycins 
in our HFIM. The use of additional read-outs such as time-to-positivity and/or most-
probable number assessment could therefore be of interest for future HFIM studies (44). 
The reliability of our results is supported by the PK results which were in line with 
what was intended. On top of that the semi-mechanistic model described the observed 
data well, enabling statistical analysis of the differences in mycobacterial killing rate at 
different rifamycin concentrations. General concern for dose finding in the HFIM is the 
availability of clinical PK information as a requirement. As such, several important PK 
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parameters including drug half-life time, absorption rate, Cmax and AUC have to be known 
beforehand. When these parameters are known, the HFIM could be a useful tool for 
dose-scheduling by finding the PK/PD parameter with optimal effect (45, 46). 
To conclude, the results of the experiments performed in a ‘standard’ HFIM, did not 
fully correspond to pre-existing clinical data of high dosing of rifampicin and rifapentine. 
The use of additional parameters and read-outs in this model could be of interest to further 
determine the place of the HFIM in the drug-development pipeline. 
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This thesis was written with the intention to improve the treatment of tuberculosis (TB) as 
the treatment of TB is prolonged and complex and treatment success rates of drug resistant 
(DR) TB are still very low. We assessed a new diagnostic test for latent TB which has been 
developed to better determine the indication for treatment (chapter 2). Furthermore, we 
assessed new treatment regimens for drug resistant TB and the value of drug potentiators 
(chapter 3.1 and 3.2). At last we assessed the applicability of two in vitro TB models to 
predict the outcomes of new TB treatment options (chapter 4.1 and 4.2).
latent tuberculosis diagnostics
In 2015 the most recent version of the QuantiFERON test was introduced in the Nether-
lands. As there is no gold standard test for latent TB it is challenging to clinically validate 
such a new test. Therefore we performed a verification study in which we compared the 
new QuantiFERON-TB gold plus (QFT-plus) to its predecessor QuantiFERON-TB gold 
in tube (QFT-GIT) (chapter 2). The QFT-GIT consists of 3 tubes for blood sampling; 
the nil-tube (negative control), the mitogen-tube (positive control) and the antigen tube 
(measuring interferon-y (INF-y) release of CD4+ T-cells). The QFT-plus is providing an 
extra antigen tube (TB2), which elicits besides a CD4+ T-cell reaction also a CD8+ T-
cell reaction. The hypothesis was that these two antigen tubes could distinguish between 
recent and old TB infections, as CD8+ T-cell INF-y release has been associated with recent 
infection (1). The study included immune competent as well as immune compromised 
patients.
The test indications were categorized as contact investigation, periodic check by oc-
cupational health services and screening before immunotherapy. In addition, some of 
the tests were performed in the context of ruling out active disease although the test is 
actually not suitable to distinguish between active and latent infection. In our study the 
agreement between both QuantiFERON-TB tests was 95%. The discordant results were 
two-sided and the majority of the discordant results were in the borderline range of the 
test results, suggesting that these differences were due to inter-test variability instead of a 
true difference between both tests. After our study, similar verification studies have been 
performed in other countries with comparable outcomes (agreement range 86.8 - 98.3%) 
(2-8). There are no other studies evaluating the test accuracy in immunocompromised 
patients. In line with our study, in two studies assessing the performances of both INF-y 
release assays in the context of health care worker screening, the agreement between the 
tests was high (95.6 and 96.6 %) with almost all discordant results in the borderline 
range (6, 8). In the two studies assessing the agreement between both tests for contact 
investigation, significantly more positive QFT-plus results were observed (4, 9), which 
might suggest that the new test is better in detecting recent infections. To explore whether 
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this was the case and if the QFT-plus could indeed differentiate between old and recent 
infections we compared the test indications with a positive test and a true difference (>0.6 
IU/ml) in INF-y release between TB1 and TB2. In this group, significantly more people 
who were expected to be more recently infected (based on their test indication) showed a 
true difference in antigen release of the antigen tubes, compared to subgroups represent-
ing more distant infections. However, only 33% of the total expected recently infected 
persons had a true difference in INF-y release. This was comparable to a previous study 
performed in Italy in which 26% of the positive tested contact investigation subjects had 
a true difference in INF-y release between TB1 and TB2 (9). Although more often a true 
difference of INF-y release between both tubes was measured in patients assumed to be 
recently infected, it does not answer the question whether we should treat a latent TB pa-
tient or not (given the low estimated sensitivity). In order to answer that question Gupta 
et al. performed a prospective cohort study to assess whether a difference in INF-y release 
between TB1 and TB2 resulted in a higher progression rate to active TB (10). In their 
study, with a median follow up of 1.93 years, 10 out of 492 patients progressed to active 
disease and no difference in progression to active disease was observed for patients with a 
higher TB2 versus TB1 INF-y release. In this respect it is reasonable to question whether 
the addition of the extra TB2 tube of QFT-plus is actually an improvement compared to 
its predecessor, as an extra blood sample has to be taken, which can be difficult in young 
children or other circumstances where blood sampling is more complex. 
Improvement of drug-resistant TB treatment
We assessed the efficacy of two promising new DR-TB regimens in our murine TB-model. 
The first combination consisted of the new TB-drugs bedaquiline and delamanid com-
bined with the recently added core second line agent linezolid (BDL) (chapter 3.1). In 
our study this combination achieved sterilization in the lungs of the mice already after 
8 weeks of treatment, while mice treated with standard therapy of isoniazid, rifampicin, 
pyrazinamide and ethambutol (HRZE) were culture negative after 20 weeks of treatment. 
More importantly, no relapse was observed after 20 weeks of BDL treatment, while in the 
HRZE group mice still relapsed at the end of the study (24 weeks). Subsequent math-
ematical modelling showed that with BDL a 95% cure rate could be achieved after 20.5 
weeks of treatment, while it was forecasted to take 28.5 weeks with HRZE. Although 
these results are promising, clinical studies should evaluate whether a treatment duration 
of less than 6 months is feasible for DR-TB. 
In our study we did not assess the additional value of each drug separately. Based on the 
monotherapy results one might question the additional value of delamanid and linezolid as 
both drugs showed only a limited decrease in colony forming unit (CFU) , which is in line 
with the results of other murine studies (11-13). However, Xu et al. showed in a mouse TB 
model that the addition of pretomanid (belonging to the same drug family as delamanid, 
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the nitroimidazoles) to the combination of bedaquiline and linezolid prevented the emer-
gence of bedaquiline resistance (14). These results might be extrapolated to our study as 
no relapse was observed after 20 weeks of treatment with the BDL regimen, while in the 
study of Xu et al. after 4 months of treatment with only bedaquiline and linezolid still 14 
out of 15 mice relapsed (14). Tasneen et al. revealed the treatment shortening potential of 
linezolid by showing that the addition of linezolid to the combination of bedaquiline and 
pretomanid resulted in no relapse in mice after 3 months of treatment, while mice treated 
with only bedaquiline and pretomanid still relapsed after 4 months of treatment (15). Not 
only in mice delamanid and linezolid showed to have additional value. In humans faster 
sputum conversion was achieved when adding delamanid to a DR-TB backbone regi-
men (16). The combination of bedaquiline, delamanid and linezolid has so far not been 
evaluated in humans. However, a study reviewing the combination of bedaquiline and 
delamanid together with a backbone regimen as DR-TB treatment in humans observed 
that after 24 weeks of treatment in 88% of the cases sputum conversion was achieved and 
92% of these patients also received linezolid (17). Furthermore, a randomized controlled 
trial in patients with XDR-TB showed that the treatment success rate in the linezolid 
therapy group was significantly higher (70%) compared to the non-linezolid group (34%) 
(18), supporting the positive outcomes of our study and its assumed clinical relevance. 
Besides, the results of the Nix-TB trial (a study assessing the combination of bedaquiline, 
pretomanid and linezolid (BPaL) in MDR and XDR-TB patients) were promising. In 
vitro, mutations have been identified that are associated with pretomanid resistance, but 
does not seem to affect delamanid susceptibility (19, 20). As such BDL might be a good 
alternative for BPaL in case of pretomanid resistance. Currently a subsequent clinical trial 
(ZeNIX) is being performed to assess whether linezolid doses can be lowered in order 
to limit toxicity (21). These results are also of interest for the clinical application of the 
BDL regimen. The WHO changed its recent guidelines concerning restricted use of the 
combination of bedaquiline and delamanid by reason of possible QT-prolongation and 
now permits its combined use when accompanied by electrocardiography surveillance as 
well as audiometry and specific biochemical tests (22). As such, the path for this powerful 
combination in the treatment of MDR- or even XDR-TB is reopened. 
The second DR-TB regimen we assessed was the combination of moxifloxacin and 
linezolid, which showed a strong CFU reduction in the lungs (5 log CFU/lung) and 
sterilization in the spleen in our mouse TB-model in only 12 weeks of treatment (chapter 
3.2). In order to assess whether the addition of an efflux pump inhibitor could increase 
the efficacy, we added the efflux pump inhibitor verapamil to this backbone regimen. 
The addition of verapamil to the moxifloxacin-linezolid combination only resulted in a 
modest additional CFU decline, but a significant reduction in spleen relapse was observed. 
Other studies showed similar effects in terms of CFU decrease with the use of verapamil in 
combination with rifampicin, isoniazid and pyrazinamide (23) and with bedaquiline (24). 
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One of these studies also showed a reduced relapse rate (23). However, the relevance of 
the reduced spleen relapse rates observed in our study is uncertain since culture positivity 
in the lungs was still observed at the end of treatment. To better evaluate the additional 
value of verapamil in reducing TB relapse rates when combined with moxifloxacin and 
linezolid, we suggest follow up studies with a longer treatment duration. Interestingly, 
in our previous in vitro study no increased activity with the addition of verapamil to the 
moxifloxacin-linezolid combination was shown (25). It might be that the effect observed 
in vivo was due to the effect of verapamil on the efflux pumps in macrophages as has been 
shown in a TB macrophage model before (26). Another reason could be the observed 
increased moxifloxacin exposure after the addition of verapamil, which has also been 
described when verapamil was combined with bedaquiline (27). As for the cause of this 
increase in AUC it was speculated that this is mediated through an effect of verapamil on 
mammalian drug transporters (27). As moxifloxacin is subject to P-glycoprotein-mediated 
efflux the increased AUC might be ascribed to the inhibition of P-glycoprotein mediated 
drug-efflux at the site of the mice intestines (28). It is important to further investigate the 
above described possible working mechanisms of efflux pump inhibitors. If the effect of 
verapamil in this study was indeed mediated by the mammalian drug transporters causing 
an increased pharmacokinetic exposure, this might increase side effects of the enforced 
drug. Despite the limited effect of verapamil in our study, the backbone of moxifloxacin 
and linezolid showed to be a promising combination in mice and a might be an interesting 
option for the treatment of DR-RB to further evaluate in clinical trials.
optimization of in vitro TB models
To evaluate new drugs and regimens for the treatment of TB, decent pre-clinical models 
which allow a good translation to clinical practice are essential to further improve the 
treatment of TB. In chapter 4 we assessed the (translational) value of two in vitro TB 
models for TB-drug activity assessment and evaluated their place in the drug-development 
pipeline. 
As one of the reasons for the long treatment duration of TB is considered to be the 
difficulty of eradicating dormant Mycobacterium tuberculosis (Mtb), it is important to as-
sess whether drugs are active against this subpopulation. In this context, good pre-clinical 
dormancy models are essential. In chapter 4.1 we described the activity assessment of 
isoniazid, rifampicin, moxifloxacin and bedaquiline in our time-kill kinetics 18b dor-
mancy model by different quantification techniques. This model uses the 18b Mtb strain 
which is dependent on streptomycin for growth. In the presence of streptomycin (STR-
exposed) the bacteria will start multiplying (fast multiplying state), when not exposed to 
streptomycin (STR-starved) the bacteria will go in a non-replicating state comparable to 
dormant Mtb. The 18b dormancy model was previously mostly used as a fast screening 
method to assess whether a drug is active against fast and non-multiplying bacteria using 
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the resazurin microplate assay (REMA) (29) and luciferase for mycobacterial load assess-
ments (30). However, these assays are limited in the assessment of cell wall inhibitors as 
those influence the conversion of resazurin in resorufin, which will cause an increase in 
fluorescence and therefore falsely influence the results (29). Besides, REMA does not allow 
time-course investigation as it is an end-point analysis. To overcome both limitations 
we used the 18b strain in a time-kill-kinetics assay during 6 days and performed CFU 
counting. We observed time-dependent activity of isoniazid and concentration- and time-
dependency of rifampicin, moxifloxacin and bedaquiline against fast and non-multiplying 
18b, which was expected based on our previous studies (25, 31, 32). To assess whether a 
TB-drug is more active on the non-multiplying bacteria compared to fast growing bacteria 
or vice versa, we used the difference in AUC (AUC of the control -unexposed- curve 
minus the AUC of the TB drug exposed curve). Assessing AUC differences allows for a 
more solid comparison between TB drug activity against both mycobacterial populations 
as this method takes into account the increase in the fast multiplying control observed 
at day 6 as opposed to the rather unchanged non-multiplying control at day 6 compared 
to day 0. This way an overestimation of TB drug activity against the non-multiplying 
population is precluded. By applying this method we confirmed that isoniazid is more 
active on STR-exposed 18b compared to STR-starved, instead of equally active as might 
have been assumed based on the similar absolute CFU decline. As these findings were in 
line with the expected performances of the drugs (25, 31, 32), the use of AUC differences 
for TB-drug activity assessment in the 18b dormancy model could be a useful additional 
read-out in time-kill kinetics studies. As it has been shown that with liquid culturing 
addition mycobacterial subpopulations can be revealed (33, 34), we included the liquid 
bacterial load assessment method time-to-positivity (TTP) by MGIT as additional read-
out. Interestingly, we observed that the TTP of the starved cultures exposed to rifampicin 
was almost similar to the TTP of the STR-exposed cultures at all concentrations tested, 
while the CFU counts of the STR-starved treated samples were considerably lower than 
the STR-exposed samples. This might be explained by the presence of a mycobacterial 
subpopulation, which is unable to grow on solid media, but can be recovered in STR-
containing liquid medium. This phenomenon has been observed previously in in vitro as 
well as in clinical studies, where a non-multiplying subpopulation was revealed by using 
another liquid based read out (most probable number) or the TTP assay as quantifica-
tion method (33, 34). This observation suggests that liquid culturing might give a better 
estimation of the total mycobacterial population present and is a useful addition to CFU 
counting, probably also for other in vitro (dormancy) models. 
Overall, our results were in line with previous studies on the activity of these drugs 
in the 18b dormancy model, except for isoniazid, which was expected as this is a cell 
wall inhibitor and could not properly be assessed by REMA and luciferase assays (30, 
35). When comparing our results to other dormancy models the results were comparable 
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to those of the hypoxic model of Wayne (36), which is in line with the similar gene 
expression profiles observed in the non-multiplying mycobacterial populations in both 
models (37). As drug activity varies substantially in different dormancy models (36), it is 
important to use different models and different quantification methods when assessing TB 
drug activity against non-multiplying mycobacterial subpopulations, which is underlined 
by the results of this study. The time-kill kinetics 18b model is relatively easy to use, with 
fast development of a non-replicating state which is relatively easy to maintain. As such 
this model has its place in the drug development pipeline as a useful preclinical model to 
assess the activity of novel compound using different read-outs. 
Another interesting possible addition to the drug development pipeline is the Hollow 
Fiber Infection Model (HFIM). In this model human pharmacokinetics can be simulated 
and samples for mycobacterial load assessment can be taken on every desired moment. In 
chapter 4.2 we assessed the place of the HFIM in the drug development pipeline by assess-
ing the activity of high dosing of rifampicin and rifapentine against drug sensitive Mtb. 
Subsequently, we back-validated our HFIM results to pre-existing data of clinical trials. 
In our study higher rifamycin exposure did not result in increased anti-mycobacterial 
activity, not even with concentrations that were expected to give toxic side-effects (38). 
This observation is in line with previous HFIM studies and comparable to our study 
these studies did not reach sterilization of the cultures due to emergence of resistance (39, 
40). In contrast, in our in vitro time-kill kinetics assays sterilization was achieved upon 
rifampicin exposure (31, 41). This might perhaps be explained by the presence of a lower 
metabolically active subpopulation in our HFIM due to the longer duration of these 
experiments. In our previous time-kill kinetics assay experiments rifampicin activity was 
lower in low compared to high metabolically active Mtb, which was associated with the 
emergence of rifampicin resistance (31, 41). This is supported by the observation of Hu 
et al. that much higher concentrations of rifampicin were required to sterilize stationary 
phase cultures compared to log-phase growth cultures (41, 42). In contrast to our HFIM 
study, in vivo studies showed an exposure response relationship for both rifamycins (43, 
44). Clinical studies were also suggestive of such an exposure response relationship which 
could only be revealed when liquid culturing was applied (45-47). However, whether this 
increased effect of higher rifampicin dosing will result in a better clinical outcome has still 
to be evaluated, since the follow up of the clinical studies assessing higher rifamycin doses 
was short and only surrogate outcome markers have been used (46, 48-50). Recently, a 
study (study 31) assessing high dose rifapentine in combination with moxifloxacin, iso-
niazid and pyrazinamide during 4 months showed non-inferiority compared to standard 
HRZE of 6 months in all analyses, suggesting that higher rifapentine dosing is indeed 
more effective (51). Various factors present in in vivo models as well as in TB patients, 
but absent in our HFIM, might be the explanation for the discrepancy in results, such as 
different mycobacterial subpopulations, immunological factors, differences in drug tissue 
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penetration and the use of different read-outs. Other studies incorporated different meta-
bolic subpopulations or Mtb infected macrophages and other intra-cellular approaches in 
the HFIM (52-54). These factors combined with the use of different mycobacterial strains 
and the use of additional read-outs such as TTP could perhaps contribute to improving 
the translational value of the HFIM. 
An important limitation is that HFIM experiments require that several PK parameters 
as drug half-life time, absorption rate, Cmax and AUC are known beforehand. When this 
information is known, it might be a useful tool for dose scheduling by assessing the PK/




In our study only 33% of the recently infected patients showed a real increase in interfer-
on-y release from the CD8+ cells. Therefore no distinction in recent and older infections 
could be made based on the new QFT-plus test. This is disappointing as a test that could 
predict these features might save a lot of unnecessary treatments. Therefore the develop-
ment of future new latent TB tests should focus on improving this particular feature. 
Possibly the recently discovered biomarker ΔHLA-DR might be an interesting target, as 
this biomarker was able to identify recent TB infection and disease progression (57). 
With regards to the current QFT-plus test, it is known that a lot of subjects peri-
odically checked by occupational health services are tested false positive and frequently 
showed to be negative after retesting (8, 58). It would be worthwhile to re-assess the 
cut-off point used for this test in the Netherlands, or introduce a borderline-range in 
order to lower the number of false positive test results. A study performed in the USA with 
low risk health care workers showed that using a more conservative interpretation of the 
QFT-plus reduced 90% of the non-reproducible positive results (8). A similar study has 
been performed for T.SPOT.TB by Rego et al. (59) and might serve as a guide for a future 
study to assess a more optimized cut-off point or borderline range for the QFT-plus when 
testing low risk subjects.
Improvement of drug resistant TB treatment
With approximately 0.5 million people who fell ill with drug-resistant(DR) TB and only 
56% of the treated patients recovered, future investments in studies aiming to increase the 
treatment success of DR-TB are highly required (60). In our mouse TB model we showed 
that the combination of the all oral TB drugs bedaquiline, delamanid and linezolid and 
also a backbone of moxifloxacin and linezolid are promising for the treatment of DR-TB, 
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with an expected relatively short treatment duration. Currently several clinical studies 
are ongoing to assess novel combinations of TB drugs (61). However not (yet) with our 
examined regimens, which will therefore be of interest. 
Various murine TB studies including a study from our research group assessed the 
combination of bedaquiline, pretomanid and linezolid (BPaL) and bedaquiline, preto-
manid, moxifloxacin and pyrazinamide (BPaMZ) (14, 15, 62). In line with the results of 
our study assessing BDL efficacy, these combinations also showed promising results and 
are already being evaluated in clinical studies. It would be of interest to assess whether the 
replacement of pretomanid by delamanid in these combinations would provide similar 
results. To our knowledge it has not been clinically evaluated whether pretomanid or 
delamanid has superior efficacy. This information might be useful as we should be aiming 
for the most effective regimen, with the least side-effects. In case of equal efficacy and 
side-effects they might be used as substitutes for each other. 
In one of our murine TB studies we also evaluated the additional value of the efflux 
pump inhibitor verapamil to the combination of moxifloxacin and linezolid. We showed 
that the addition of verapamil resulted in only a modest additional CFU decline and in 
significantly less relapse in the spleen. However, as the lungs of the mice were still culture 
positive at the end of treatment, the clinical relevance of this finding is questionable. 
Previous murine studies of our group on the use of the efflux pump inhibitors thioridazine 
and SILA-421 showed disappointing results (63, 64). Other studies did show that the 
addition of verapamil to bedaquiline might reduce TB relapse rates (24). Importantly, 
in this study the addition of verapamil increased bedaquiline exposure similar to what 
was observed in our study for moxifloxacin. If increased efficacy is indeed related to the 
increased exposure to bedaquiline or moxifloxacin by verapamil addition, why not just 
increase the dose of these drugs instead of adding an extra drug which might provide extra 
side-effects. 
Currently, the search for dose optimization is gaining more interest. In our HFIM we 
showed that increasing the dose of rifampicin and rifapentine did not result in increased 
activity, although clinical studies so far suggest otherwise (45-49). In this context, study 
31 showed that higher dosing of rifapentine could reduce the treatment duration of 
drug susceptible TB with 2 months (51). Besides in the ZeNIX trial is currently assessed 
whether the dose of linezolid could be lowered in the combination with bedaquiline and 
pretomanid to limit toxicity while containing efficacy. These dose optimization studies are 
useful additions for the treatment optimization of TB and should be further explored as 
limited new drugs have entered the marked in the last decades or are expected in the near 
future.
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optimization of pre-clinical models
Several research consortia are aiming to provide an optimal research path assessing novel 
TB drugs and drug regimens by combining several pre-clinical models. We assessed the 
place of two of those pre-clinical models in the pre-clinical drug-development pipeline 
and showed that the 18b dormancy model in its current form is a useful tool to assess drug 
activity against fast and non-replicating Mtb in the early stage of drug development. The 
place of the HFIM in the drug development pipeline is more difficult to determine, due 
to its dependence on clinical PK/PD information. Furthermore, in our study the trans-
lational value of the HFIM results was limited. As previously suggested this translational 
value might increase by the use of additional outcome parameters and the inclusion of 
more parameters such as different mycobacterial subpopulations. In this context, we and 
other research groups used the 18b strain in the HFIM for assessment of drug activity 
against mycobacteria in the non-replicating state (52, 65). However, in these experiments 
the mycobacterial load of the control culture declined significantly during the experiments 
(52, 65) and we observed a substantial amount of regrowth of mycobacteria that became 
independent of streptomycin for growth (unpublished results). Therefore, the 18b strain 
should only be used for short course experiments. Consequently, we should search for a 
better dormancy model to use in the HFIM. As such, potassium or nutrient depletion 
might be good alternatives to assess in the future (66, 67). Also using lipid-rich medium 
in the HFIM might be an interesting option, as within this lipid-rich dormancy model 
the mycobacteria will represent a dormant phenotype with a dormancy gene expression 
profile, but are still culturable (68). Besides, it will be interesting to evaluate the additional 
value of incorporating macrophages and other intracellular approaches in the HFIM, in 
order to increase its translational value. 
To increase the predictive value of preclinical models it is essential to include different 
mycobacterial subpopulations. In addition, it is important to include different read-outs 
for the optimal identification of the total mycobacterial population present. Several stud-
ies have shown that applying liquid culturing increased detection (33, 34, 69). Therefore 
it is recommended to include different outcome parameters in all pre-clinical models, to 
better estimate drug activity and efficacy on the total mycobacterial population. By gain-
ing more knowledge about drug activity against different subpopulations, more targeted 
regimens can be made. For example by including in the first phase mainly drugs that act 
on the fast-multiplying population and in the later phase drugs that act against the non-
multiplying population, to limit the pill load and side-effects. In this context we should 
aim for an outcome parameter that is able to reveal the total mycobacterial population. 
The mycobacterial load (MBL) assay, based on the detection of 16s ribosomal RNA, is 
expected not to be influenced by the metabolic state of mycobacteria and might therefore 
measure the bacterial load more precisely, which has been suggested in murine as well as 
clinical studies (69, 70). 
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optimal pre-clinical drug development pipeline
Based on the findings of our research the optimal pre-clinical drug development pipeline 
might be filled in as follows:
After  a new possible lead is found, one should start with assessment of the minimal 
inhibitory concentration (MIC). Based on the MIC a TKK assay with the clinical Beijing 
strain should be performed, in order to assess concentration and time-dependent activity 
and eventually early emergence of resistance. The next step would be a TKK assay with the 
use of the 18b strain including the use of our new AUC approach and TTP measurement, 
in order to assess the activity of the new drug against dormant M. tuberculosis and possible 
other subpopulations that can only be cultured in liquid medium. Based on these results 
EBA studies in our mouse TB model can be performed during 6 weeks, with different drug 
concentrations. Also in this phase it is important to include different outcome parameters, 
like CFU, TTP and MBL in order to assess the drug activity on different subpopulations. 
Also combination regimens can be assessed in our mouse TB model, where the focus 
should be on the relapse assessment. Subsequently mathematical modelling can be useful 
for treatment duration assessment as last step before studies in humans. 
summAry
In all, with this thesis we provided useful information and tools to improve the treatment 
of tuberculosis. Further research in this field should focus on:
•	 Preventing unnecessary treatment of latent TB by developing a test which can predict 
the chance of progression to active disease.
•	 Dose optimization should have a prominent place in the development of new regimens 
and pre-clinical models should be further improved for this assessment.
•	 Including different mycobacterial subpopulations and improving and using different 
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In dit proefschrift worden verschillende onderzoeken beschreven die als doel hebben de 
behandeling van tuberculose (TB) te verbeteren. Het is bekend dat patiënten met latente 
TB (besmet met Mycobacterium tuberculosis maar (nog) niet ziek), vooral baat hebben bij 
behandeling wanneer zij recent geïnfecteerd zijn. Dit komt doordat het risico op actieve 
TB na besmetting het grootst is in de eerste twee jaar na infectie. Echter het aantonen 
wanneer iemand besmet is geraakt is niet goed mogelijk. Daarom hebben we een nieuwe 
test voor de diagnostiek van latente TB onderzocht die is ontwikkeld om een onderscheid 
te maken tussen recente en oudere infectie om zodoende de behandelindicatie beter vast 
te kunnen stellen (hoofdstuk 2).
Het volgende probleem waarop het onderzoek in dit proefschrift gericht is, is dat mo-
menteel de behandeling van actieve TB complex is met een behandelduur van minimaal 
6 maanden met 4 verschillende middelen. Deze therapieduur moet nog eens verlengd 
worden tot minimaal 9 maanden en soms zelfs tot 2 jaar met heel veel verschillende 
antibiotica wanneer dit zorgt voor een hoge behandellast, bijwerkingen en afname van 
de therapietrouw. De behandeling is dan ook met name bij patiënten met resistente TB 
in veel gevallen niet succesvol. Daarom hebben we nieuwe behandelregimes onderzocht 
voor resistente TB met als doel de behandelduur te verkorten en het aantal middelen te 
verlagen. Ook hebben we gekeken naar  de rol  van zogeheten drug potentiators, middelen 
die de werking van antibiotica kunnen versterken (hoofdstuk 3.1 en 3.2). 
Voor het onderzoeken van deze nieuwe regimes is het van belang om te beschikken over 
goede preklinische modellen met een hoge translationele (voorspellende) waarde, waarin 
deze nieuwe regimes getest kunnen worden. Daarvoor hebben we de toepasbaarheid van 
twee preklinische TB modellen onderzocht (hoofdstuk 4.1 en 4.2). 
In hoofdstuk 2 hebben we onderzocht of de resultaten van de nieuwe latente TB test 
QuantiFERON Gold Plus (QFT-plus) vergelijkbaar waren met zijn voorganger de Quan-
tiFERON Gold In Tube (QFT-GIT), hetgeen in 95% van de testen het geval was. Deze 
nieuwe test is ontwikkeld om een beter onderscheid te kunnen maken tussen een recente 
TB infectie en een infectie die langer geleden opgelopen is. Hiervoor is er een extra anti-
geenbuis aan de QFT-plus toegevoegd die naast de interferon-y release van CD4+ T-cellen 
ook de interferon-y release van CD8+ T cellen meet, welke geassocieerd is met een recente 
infectie. Om te onderzoeken of deze test daadwerkelijk dit onderscheid tussen recente en 
oudere infectie kan maken hebben we bij alle positieve testen van ons onderzoek gekeken 
of er daadwerkelijk een verschil was in de gemeten hoeveelheid interferon-y tussen de 
twee antigeen buizen. Hierbij vonden we significant vaker een verschil in interferon-y 
release tussen de twee antigeenbuizen bij patiënten die vermoedelijk recent besmet waren. 
Dat betekent echter niet dat de QFT-plus gebruikt kan worden om het onderscheid te 
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maken tussen een recente dan wel oudere infectie aangezien dit slechts in 33% van de 
vermoedelijk recent geïnfecteerde patiënten het geval was. 
In hoofdstuk 3 hebben we de effectiviteit van twee nieuwe combinaties van antibiotica 
voor de behandeling van antibiotica resistente TB onderzocht. In hoofdstuk 3.1 hebben 
we gekeken naar de effectiviteit van de combinatie van de nieuwe tuberculosemiddelen 
bedaquiline en delamanid samen met linezolid (BDL). Dit regime hebben we getest in 
ons muis-TB model, waarbij we gedurende 24 weken de effectiviteit van het regime getest 
hebben door tijdens behandeling elke 4 weken de mycobacteriële load in de longen en 
milt van 3 van de muizen te bepalen. Om de 2 weken hebben we de behandeling van 3 
muizen gestaakt en vervolgens na 12 weken zonder behandeling de mycobacteriële load 
in de longen en milt bepaald. De BDL combinatie bleek erg effectief waarbij in een vroeg 
stadium (na 20 weken behandeling) geen TB relapse (12 weken na behandeling nog steeds 
geen M. tuberculosis aantoonbaar) meer gezien werd en er dus sprake was van genezing. 
De potentie van dit nieuwe regime is hoog vergeleken met de standaard TB behandeling 
(isoniazide, rifampicine, pyrazinamide en ethambutol) waarbij er zelfs na 24 weken be-
handeling nog steeds sprake was van relapse. Vervolgens hebben we data gemodelleerd om 
een uitspraak te kunnen doen over de te verwachten behandelduur met het nieuwe regime. 
Hieruit bleek dat de BDL behandeling naar verwachting 8 weken sneller tot genezing 
zal leiden dan de standaard behandeling. Antwoord op de vraag of de behandelduur van 
resistente TB met BDL daadwerkelijk korter zou kunnen zijn dan de huidige behandeling 
van niet-resistente TB zal nog uit klinische studies moeten blijken. Ook de combinatie 
van moxifloxacin en linezolid (hoofdstuk 3.2) leek effectief voor de behandeling van 
TB in ons muis-TB model, waarbij we een snelle afname van de mycobacteriële load 
(colony forming units (CFU)’s) zagen. De behandelduur van 14 weken in ons experiment 
was echter te kort om de mycobacteriën in de long te elimineren, waardoor we geen 
uitspraak over de mate van relapse konden doen. Omdat uit eerdere studies gebleken is 
dat effluxpompremmers mogelijk de werking van bepaalde tuberculosemiddelen kunnen 
versterken, door het remmen van de effluxpompen van macrofagen, maar ook die van M. 
tuberculosis zelf, hebben we gekeken of de effluxpompremmer verapamil de effectiviteit 
van de moxifloxacin-linezolid combinatie kon verbeteren. Dit leidde echter nauwelijks 
tot een grotere afname van het aantal CFU’s. Om de exacte waarde van deze bevinding 
te onderzoeken zou de studie herhaald moeten worden met een langere behandelduur en 
follow up. 
Om de activiteit en effectiviteit van nieuwe TB-middelen en -regimes te kunnen 
onderzoeken zijn goede preklinische modellen met een hoge translationele waarde van 
essentieel belang. M. tuberculosis kan zich afhankelijk van de omstandigheden snel delen, 
langzaam of helemaal niet. Wanneer de bacteriën niet meer delen noemen we deze me-
tabole toestand dormant (slapend). Het is bekend dat wanneer M. tuberculosis dormant 
is, het veel minder gevoelig is voor antibiotica, wat ook één van de redenen is dat de 
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behandelduur van TB zo lang is. Om de therapieduur te verkorten ligt daarom de focus 
van veel preklinisch onderzoek op het effectiever behandelen van deze mycobacteriële 
populatie. Derhalve is het van belang om goede preklinische modellen te hebben die deze 
metabole toestand goed kunnen simuleren en daarmee ook betrouwbare voorspellingen 
te kunnen doen ten aanzien van de effectiviteit van de behandeling in patiënten. Het 
nabootsen van deze metabole toestand is in veel in vitro modellen een tijdrovende en 
complexe zaak. Er bestaat echter een M. tuberculosis stam (18b) die voor zijn groei afhan-
kelijk is van de aanwezigheid van streptomycine. In afwezigheid van streptomycine, stopt 
deze M. tuberculosis binnen 10 dagen met delen en zal er een volledig dormant populatie 
ontstaan. Deze 18b stam hebben wij gebruikt om de activiteit van de middelen isoniazide, 
rifampicine, moxifloxacin en bedaquiline te onderzoeken, hetgeen in hoofdstuk 4.1 bes-
chreven staat. Hiervoor hebben we met de 18b stam in zowel dormant als actief delende 
toestand verschillende time-kill kinetics assays uitgevoerd. Hierbij hebben we de actieve 
en de dormant populatie gedurende 7 dagen aan verschillende concentraties antibiotica 
blootgesteld en op verschillende dagen samples genomen om de hoeveelheid CFU’s te 
bepalen. Om een goede vergelijking te kunnen maken tussen het effect van de verschil-
lende antibiotica op de actief delende  en dormant 18b hebben we een nieuwe methode 
gebruikt. Hierbij is gekeken naar het verschil in de area under the curve (AUC) tussen de 
onbehandelde en de behandelde samples. Hiermee konden we aantonen dat rifampicine 
het meest actief was tegen dormant 18b, waarbij er vrijwel geen verschil in activiteit van 
rifampicine was tegen actieve en dormant 18b. Omdat sommige subpopulaties van M. 
tuberculosis beter identificeerbaar zijn in vloeibaar medium hebben we ook de samples 
van dag 0 en dag 6 in vloeibaar medium gekweekt om de tijd nodig tot groei te bepalen. 
De resultaten suggereerden dat er mogelijk een extra subpopulatie van M. tuberculosis 
binnen de dormant 18b populatie in de rifampicine behandelde groep aanwezig was, die 
alleen in vloeibaar medium aangetoond kon worden. Op basis van de resultaten van deze 
studie concluderen we dat onze 18b time-kill-kinetics assay een nuttig model is voor het 
evalueren van de activiteit van tuberculosemiddelen tegen M. tuberculosis in verschillende 
metabole toestanden. Daarnaast heeft ons onderzoek het belang laten zien van het meten 
met meerdere uitkomstmaten, aangezien dit meer inzicht geeft in het effect van de antibi-
otica op meerdere mycobacteriële subpopulaties. 
In hoofdstuk 4.2 hebben we de activiteit van hoge doseringen rifampicine en rifa-
pentine getest in ons hollow fiber infection model (HFIM). Dit is een model waarin de 
menselijke farmacokinetiek nagebootst kan worden en op elk willekeurig moment samples 
genomen kunnen worden om de mycobacteriële load te bepalen. Om de plaats van dit 
model in het preklinisch onderzoek naar de potentie van TB middelen beter te kunnen 
bepalen hebben we de resultaten van onze experimenten vergeleken met de resultaten van 
klinische trials. 
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In ons HFIM zagen we vrijwel geen concentratie-afhankelijke effecten voor beide 
rifamycines. Dit komt overeen met de resultaten van andere HFIM studies, maar is in 
tegenspraak met de resultaten van klinische studies, die wel meer effectiviteit lieten zien 
wanneer er hogere doseringen gebruikt werden. In de klinische studies is deze concentra-
tieafhankelijkheid alleen significant aangetoond indien er vloeibare kweken bij patiënten 
waren afgenomen, maar niet voor de CFU resultaten. Mogelijk is dit ook een van de 
redenen waarom wij dit effect niet in ons HFIM konden aantonen, aangezien we alleen 
CFU’s gemeten hebben. Daarnaast zijn bij TB patiënten vele factoren van invloed op de 
respons op antibiotica, die in onze HFIM experimenten nu niet meegenomen zijn, zoals 
de aanwezigheid van meerdere metabole subpopulaties, intracellulaire bacteriën, verschil-
len in weefselpenetratie en verschillende immunologische factoren. Deze factoren kunnen 
ook bijdragen aan de gevonden verschillen tussen de uitkomsten in het HFIM en klinische 
studies. 
Kortom, de resultaten van hogere doseringen rifamycines in een standaard HFIM 
kwamen niet volledig overeen met bestaande klinische data. Hierdoor is de plaats van het 
HFIM in deze vorm binnen het preklinisch onderzoek nog niet helemaal duidelijk, maar 
lijkt het HFIM het meest bruikbaar voor het maken van doseerschema’s door de PK/PD 
parameter te achterhalen welke het meeste effect sorteert. Om de translationele waarde 
van het HFIM te verhogen zou het interessant zijn om andere factoren in het model te 
incorporeren zoals geïnfecteerde macrofagen, of verschillende metabole populaties.
Concluderend, hebben we door de hierboven beschreven onderzoeken meer inzicht 
gekregen in de diagnostiek, en potentiële nieuwe behandelingen  van TB. Waarbij we 
de nieuwe QuantiFERON test hebben gevalideerd, maar deze helaas niet in staat bleek 
de behandelindicatie beter vast te stellen. Verder hebben we aangetoond dat BDL een 
veelbelovende nieuwe behandelcombinatie voor resistente TB is, evenals de moxifloxacin-
linezolid combinatie. De toegevoegde waarde van verapamil als drug-potentiator bleek 
echter beperkt. Ons 18b TKK model lijkt een toegevoegde waarde te hebben binnen het 
preklinisch onderzoek, terwijl de resultaten van het HFIM in zijn huidige vorm in dat 
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je hulp op het lab, maar ook in de laatste fase met het maken van grafieken en het oplossen 
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van problemen die ik vanuit huis niet goed kon regelen. Behalve dat ik altijd alles aan je 
kon vragen, was het ook altijd erg gezellig om even het weekend door te nemen en de 
vorderingen qua hardlooptrainingen te horen. Corné ook jij hebt mij enorm geholpen 
met het aanleren van labvaardigheden, helaas is ons MBL project nooit echt een succes 
geworden, maar dat lag in elk geval niet aan de inzet. Gerjo, je bent natuurlijk al even weg 
bij de MMIZ, maar je hebt me tijdens het opstarten van mijn onderzoek met veel van de 
procedures wegwijs gemaakt en het was leuk je laatst in je nieuwe rol in het AMC tegen te 
komen, helaas is dat koffietje er door COVID niet meer van gekomen, maar wie weet in 
de toekomst. Heleen, dank voor je hulp bij de muizenstudies. Marjan, dank voor de fijne 
tijd in ‘jouw’ lab. Je hebt me veel over labwerk geleerd en stond altijd klaar om te helpen. 
Sanne, bedankt voor jouw hulp bij ons hollow fiber project. Van jou heb ik echt geleerd 
hoe belangrijk het is op het lab om precies te werken, zaken te standaardiseren en duidelijk 
procedures te beschrijven. Dit heeft er zeker voor gezorgd dat de voorbereiding voor veel 
projecten goed was, waardoor de experimenten ook beter verliepen. 
Maarten, inmiddels zelf al bijna phd student af, maar je hebt mij tijdens je masteron-
derzoek deed ontzettend goed geholpen met de 18b studie. Je hebt een hele leuke creatieve 
kijk op dingen, waardoor je met veel mooie nieuwe onderzoeksideeën kwam. Daarnaast 
was je ook een erg gezellige collega en bureaubuurman. Gelukkig lijken onze phd projec-
ten toch iets beter te verlopen dan ons avocadoplant project..
Rixt, wat bofte ik toen ik naast jou terecht kwam toen ik begon met mijn phd traject. 
Jij was ook net begonnen en dat schepte meteen een band. Ik had altijd zin om na het 
weekend weer even bij te kletsen over alles, waarbij soms de halve ochtend alweer voorbij 
was voor we echt aan het werk gingen. Ik heb je erg gemist toen je opeens naar Australië 
ging, maar het was leuk om te horen hoe het leven daar was en hoe erg je daarvan genoten 
hebt. Ik ben blij dat we elkaar nog steeds spreken en dat ik af en toe een update over mijn 
pannekoekenplant baby krijg.
Hassna, ook wij begonnen ongeveer tegelijkertijd aan ons onderzoek, helaas ging jij 
alleen al een stuk eerder weg. Vond het altijd erg gezellig met je en leuk dat we nu waar-
schijnlijk toch ongeveer tegelijk ons proefschrift gaan verdedigen. 
Carla, bedankt voor het voorbereiden van de honderden liters platen en broth..
Verder wil ik graag alle andere medewerkers van de MMIZ bedanken. In de afgelopen 
6 jaar die ik hier gewerkt heb, heb ik een ontzettend fijne, leerzame en gezellige tijd gehad 
zowel als oudste coassistent, masteronderzoekstudent en als phd student. 
Verder wil ik de arts-assistenten van de interne geneeskunde in het Franciscus bedan-
ken voor de flexibiliteit met de roosters, waarbij ik erg veel (avond)diensten heb kunnen 
doen, waardoor ik genoeg tijd heb gehad om mijn proefschrift af te ronden. Daarbij was 
er niet meer zoveel tijd (en mogelijkheid door COVID) om privé leuke dingen te doen, 
maar was het gelukkig op werk wel altijd erg gezellig.
163Dankwoord
Tiarah, het was altijd heerlijk om tussen de experimenten door weer even samen te 
lunchen ergens tussen het EMC en het oogziekenhuis in en ben heel blij dat we nu niet 
alleen een stuk dichter bij elkaar wonen maar nu ook nog in hetzelfde ziekenhuis werken!
Pauline, dank voor onze vriendschap van de afgelopen 18 Jaar. Het is altijd een wel-
kome afwisseling om het over heel andere zaken dan medische dingen te hebben, maar 
tegelijkertijd was je ook altijd erg betrokken bij hoe mijn onderzoek vorderde.
Annelie, Charlotte, Dana, Lara, Lesley, Lise, Marieke, Solange en Warnyta, dank voor 
alle keren dat we pas om half 9 gingen eten omdat ik nog uit Rotterdam moest komen, 
jullie blijvende interesse in de totstandkoming van dit proefschrift en de fantastische stu-
dententijd die ik met jullie gehad heb. Annelie in het bijzonder ook dank voor jou omdat 
zonder jouw logeerkamer de logistiek ten aanzien van mijn hollow fiber experimenten 
een stuk problematischer was geweest en de daarbij behorende etentjes maakten deze 
onderzoeksavonden ook meteen een stuk gezelliger. 
Verder wil ik ook graag mijn schoonouders, Willem en Ineke bedanken voor jullie 
interesse in mijn onderzoek, de vele artikelen over tuberculose die ik van Willem doorge-
stuurd kreeg en onze gesprekken over onderzoek en wetenschap in het algemeen. Daarbij 
zijn jullie natuurlijk een belangrijke steun geweest bij de zorg voor Philip in het afgelopen 
drukke jaar.
Mijn broertjes, Kay en Roel en nu ook mijn paranimfen. Het was heel gezellig om 
de afgelopen jaren samen met jullie te studeren in het EMC, lunchen en alle hoogte en 
dieptepunten van onze studie te kunnen delen. 
Mijn zusje Myrthe, dank voor alle logeerpartijen als ik weer eens tot laat experimenten 
moest doen en niet meer met de trein naar Amsterdam kon. Jammer dat er nu je werkt 
geen tijd meer is voor lekkere lunchmomentjes bij Vermeyden, maar dat moeten we ge-
woon wat vaker in het weekend gaan plannen. 
Papa en mama, dankzij jullie heb ik een heerlijke jeugd gehad, wat natuurlijk de 
belangrijkste basis is geweest voor mijn verdere ontwikkeling later en dus ook voor dit 
boekje. Mama, het was heel leuk om het met jou het over mijn onderzoek te hebben en 
hoe jij door mijn onderzoek weer nieuwe ideeën kreeg voor de oncologie. Papa, het was 
natuurlijk enorm gezellig om met jou in hetzelfde ziekenhuis te werken ook al kwamen we 
elkaar vrijwel nooit spontaan tegen. Ik mis onze regelmatige lunches. Daarbij ben ik jullie 
enorm dankbaar voor jullie goede zorg voor Philip in het afgelopen jaar, waardoor ik altijd 
met een fijn gevoel naar mijn werk kan. 
Lieve Philip, jij hebt natuurlijk geen echte bijdrage aan dit boekje geleverd, maar wel 
mijn leven nog een stuk mooier gemaakt dan het al was. 
Bart, jij bent onmisbaar geweest in dit hele traject. Je hebt me altijd gestimuleerd om 
alles te doen wat ik wil, ook al zorgde dat ervoor dat ik de afgelopen jaren erg veel aan het 
werk en studeren was. Jij zorgde ervoor dat dit mogelijk was en alles thuis soepel verliep. 
Ik kan me niemand beters naast mij wensen. 
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